pncA Resolved · high auto-curated

H37Rv Rv2043c · MTBC0 mtbc0_002176 · 186 aa · 2317294–2317854 MTBC0 (-) · RefSeq NP_216559.1

Genomic neighbourhood (genome browser)

Open in full genome browser →

This gene (outlined) in its genomic context; arrows are neighbouring genes coloured by verdict. Click any gene to navigate. Pan and zoom in the full browser.

Annotation: from legacy to revised

Legacy (H37Rv / Mycobrowser)pyrazinamidase/nicotinamidase PncA
MTBC0 PGAP re-annotationpyrazinamidase PncA
Revised (this work)Pyrazinamidase PncA. Pfam: Isochorismatase (PF00857.27).
Functional category (TubercuList)intermediary metabolism and respiration

Auto-curated: this verdict and function were generated by rules from PGAP + Pfam + Foldseek and have not been hand-reviewed.

In the literature (TB corpus sweep) 433 publications

433 TB publications mention this gene. 433 publications discuss this gene. Queried separately, 431 records carry a M. tuberculosis context and 12 a non-TB mycobacterial context (species named in the 12-record verified sample: M. smegmatis (9), M. marinum (2), M. abscessus (1), M. leprae (1)). The three counts come from three distinct PubMed queries (each with its own context filter), so they neither partition the total nor need to add up to it.

5 of 433: the most recently indexed records of the curated sweep at its date, not necessarily the most recent papers on this gene — the exhaustive list below is later and broader and may hold newer ones.
PublicationDate
Toward precision detection of pyrazinamide resistance: critical concentration assessment and rapid molecular method validation. doi:10.3389/fmicb.2026.1828630 2026
Pyrazinamide susceptibility testing in Mycobacterium tuberculosis: impact of false-positive BD MGIT 960 results and added value of sequencing for accurate diagnosis in a low-MDR-TB-incidence context. doi:10.3389/fcimb.2026.1777714 2026
Genetic Characterization of First-Line Drug-Resistance Mutations in Multidrug-Resistant Mycobacterium tuberculosis. doi:10.3390/pathogens15050455 2026
Effects of mutations conferring pyrazinamide resistance among multidrug-resistant tuberculosis isolates from China. doi:10.1128/spectrum.00641-26 2026
Evaluation of DNA extraction methods from clinical Mycobacterium tuberculosis primary liquid culture for whole-genome sequencing. doi:10.1186/s12864-026-12812-w 2026
452 records returned by the alias sweep (a separate sweep from the 433 above; both are shown, neither is exhaustive)

Searched as: Rv2043c, pncA, Mb2069c, MMAR_3016, MSMEG_6506, MAB_1472c — each in conjunction with a mycobacterial context term. Swept 2026-09-07.

PublicationJournalYear
Genomic epidemiology of the Mycobacterium tuberculosis complex in Fiji reveals community transmission and human Mycobacterium bovis infection. doi:10.3389/fmicb.2026.1933597 Front Microbiol 2026
Comparative whole genome analysis of Mycobacterium tuberculosis isolated from BPaLM and individualized regimen treated patients at Dr. Soetomo Hospital, Indonesia. doi:10.1007/s11033-026-12652-7 Mol Biol Rep 2026
Molecular Mechanisms Underlying Antimicrobial Resistance in Mycobacteria. doi:10.3390/ijms27156893 Int J Mol Sci 2026
Whole-genome sequencing reveals lineage-associated drug resistance and enables machine learning-based prediction in Mycobacterium tuberculosis clinical isolates. doi:10.3389/fmicb.2026.1828991 Front Microbiol 2026
Kinetical Analysis of Mutant PZase Enzyme To Uncover The Pyrazinamide Resistance In Mycobacterium tuberculosis Clinical Isolates. New Microbiol 2026
Toward precision detection of pyrazinamide resistance: critical concentration assessment and rapid molecular method validation. doi:10.3389/fmicb.2026.1828630 Front Microbiol 2026
Pyrazinamide susceptibility testing in Mycobacterium tuberculosis: impact of false-positive BD MGIT 960 results and added value of sequencing for accurate diagnosis in a low-MDR-TB-incidence context. doi:10.3389/fcimb.2026.1777714 Front Cell Infect Microbiol 2026
Genetic Characterization of First-Line Drug-Resistance Mutations in Multidrug-Resistant Mycobacterium tuberculosis. doi:10.3390/pathogens15050455 Pathogens 2026
Effects of mutations conferring pyrazinamide resistance among multidrug-resistant tuberculosis isolates from China. doi:10.1128/spectrum.00641-26 Microbiol Spectr 2026
Evaluation of DNA extraction methods from clinical Mycobacterium tuberculosis primary liquid culture for whole-genome sequencing. doi:10.1186/s12864-026-12812-w BMC Genomics 2026
Association of pyrazinamide resistance in Mycobacterium tuberculosis with mutations in rpoB, katG, and inhA genes. doi:10.1038/s41598-026-53296-8 Sci Rep 2026
First-line drug-resistant tuberculosis among children under 15 years in Ethiopia: insights from phenotypic and whole-genome sequencing approaches. doi:10.1186/s12879-026-13206-9 BMC Infect Dis 2026
Comparative transcriptomic profiling of pyrazinamide resistance in Mycobacterium tuberculosis. doi:10.1093/jambio/lxag064 J Appl Microbiol 2026
Predicting pyrazinamide resistance in Mycobacterium tuberculosis using a graph convolutional network. doi:10.1186/s12866-026-04876-1 BMC Microbiol 2026
Genetic and immunologic determinants of BCG disease: from mechanism to prevention. doi:10.1080/07853890.2026.2634548 Ann Med 2026
Association between overexpression of efflux pumps genes Rv0191 and Rv3008 and pyrazinamide resistance in multidrug-resistant Mycobacterium tuberculosis: a multi-center study. doi:10.1186/s12879-026-12793-x BMC Infect Dis 2026
Targeting Mycobacterium tuberculosis: The Role of Alkyl Substitution in Pyrazinamide Derivatives. doi:10.1021/acsomega.5c07249 ACS Omega 2026
Characterization of pulmonary tuberculosis in high-altitude region using nanopore targeted sequencing. doi:10.1186/s12866-026-04761-x BMC Microbiol 2026
Whole Genome Sequencing Analysis Revealed High Genetic Diversity and Drug-Resistant Characteristics of Mycobacterium bovis From Chinese Farms. doi:10.1111/zph.70026 Zoonoses Public Health 2026
Machine learning approaches to predict drug resistance in tuberculosis. doi:10.1016/j.compbiolchem.2025.108705 Comput Biol Chem 2026
Drug resistance profile of Mycobacterium tuberculosis in China: update until 2024. doi:10.3389/fmicb.2025.1697490 Front Microbiol 2025
Molecular Epidemiology of Mycobacterium tuberculosis in Mexico. doi:10.3390/microorganisms13112453 Microorganisms 2025
Genomic characterization of XDR Mycobacterium tuberculosis isolates in Argentina (2006-2015). doi:10.1186/s12879-025-11913-3 BMC Infect Dis 2025
Characterization of Drug Resistance Mutations in Mycobacterium tuberculosis Isolates from Moroccan Patients Using Deeplex Targeted Next-Generation Sequencing. doi:10.3390/microorganisms13092163 Microorganisms 2025
Genomic insights into pyrazinamide and fluoroquinolone resistance in multidrug-resistant tuberculosis in Khyber Pakhtunkhwa, Pakistan. doi:10.1016/j.ijmm.2025.151674 Int J Med Microbiol 2025
Enhancing diagnostic efficiency of pyrazinamide resistance in Mycobacterium tuberculosis via modified MGIT assay and genotypic correlation. doi:10.1016/j.crmicr.2025.100462 Curr Res Microb Sci 2025
S292L mutation in Rv1258c efflux pump drives pyrazinamide efflux and a novel inhibitor designed for co-therapy to improve MDR-TB treatment outcomes. doi:10.1007/s11274-025-04510-8 World J Microbiol Biotechnol 2025
Whole-genome sequencing for analyzing the transmission characteristics of drug-resistant Mycobacterium tuberculosis in Ganzhou, China. doi:10.1186/s12879-025-11356-w BMC Infect Dis 2025
Lineage identification and mutation profile of Mycobacterium tuberculosis: A study from National Reference Laboratory, India. doi:10.1016/j.ijmmb.2025.100925 Indian J Med Microbiol 2025
The Identification of Novel Mutations in ATP-Dependent Protease ClpC1 Assists in the Molecular Diagnosis of Obscured Pyrazinamide-Resistant Tuberculosis Clinical Isolates. doi:10.3390/microorganisms13061401 Microorganisms 2025
Evolutionary Genetic Analysis of the Pyrazinamidase Gene in Seven Global Populations of Mycobacterium tuberculosis. doi:10.4103/ijmy.ijmy_30_25 Int J Mycobacteriol 2025
Investigation of potential relationship betweenmazEF3, relJK, and vapBC3 genes and antimicrobial resistance inMycobacterium bovis. doi:10.1186/s12879-025-11168-y BMC Infect Dis 2025
Comprehensive evaluation of the MeltPro MTB/PZA assay for prediction of pyrazinamide resistance in multidrug-resistant tuberculosis. doi:10.1128/spectrum.02745-24 Microbiol Spectr 2025
Whole-genome sequencing analysis to identify antimicrobial resistance regions and virulence factors in Mycobacterium tuberculosis isolates from the Amhara Region, Ethiopia. doi:10.1038/s41598-025-01241-6 Sci Rep 2025
Tuberculosis in Malaysia: Disease timeline, epidemiology, control initiatives and outlook. Malays J Pathol 2025
Prevalence and Clinical Implications of Pyrazinamide Resistance in Newly Diagnosed TB Patients in Uganda. doi:10.2147/IDR.S491770 Infect Drug Resist 2025
Whole genomic analysis uncovers high genetic diversity of rifampicin-resistant Mycobacterium tuberculosis strains in Botswana. doi:10.3389/fmicb.2025.1535160 Front Microbiol 2025
Genetic diversity and transmission pattern of multidrug-resistant tuberculosis based on whole-genome sequencing in Wuhan, China. doi:10.3389/fpubh.2025.1442987 Front Public Health 2025
The epidemiology and gene mutation characteristics of pyrazinamide-resistant Mycobacterium tuberculosis clinical isolates in Southern China. doi:10.1080/22221751.2024.2447607 Emerg Microbes Infect 2025
Phylogenetically Informative Mutations in Drug Resistance Genes of Human-Infecting Mycobacterium bovis. doi:10.1155/2024/5578214 Transbound Emerg Dis 2024
Phenotypic and genotypic characterization of Mycobacterium tuberculosis pyrazinamide resistance-India, 2018-2020. doi:10.3389/fmicb.2024.1515627 Front Microbiol 2024
A simplified pyrazinamidase test for Mycobacterium tuberculosis pyrazinamide antimicrobial susceptibility testing. doi:10.1128/jcm.01227-24 J Clin Microbiol 2024
Analysis of genetic characteristics associated with reduced bedaquiline susceptibility in multidrug-resistant Mycobacterium tuberculosis. doi:10.1016/j.tube.2024.102572 Tuberculosis (Edinb) 2024
Mycobacterium tuberculosis evolution from monoresistance to pre-extensive drug resistance during a prolonged household outbreak. doi:10.1016/j.jctube.2024.100482 J Clin Tuberc Other Mycobact Dis 2024
Genetic diversities and drug resistance in Mycobacterium bovis isolates from zoonotic tuberculosis using whole genome sequencing. doi:10.1186/s12864-024-10909-8 BMC Genomics 2024
Genome sequencing analysis of the pncA, rpsA and panD genes responsible for pyrazinamide resistance of Mycobacterium tuberculosis from Indonesian isolates. doi:10.1111/tmi.14051 names it Trop Med Int Health 2024
Pyrazinamide resistance due to pncA gene mutation and its association with treatment outcome among tuberculosis patients of South India- A longitudinal observational study. doi:10.1016/j.ijtb.2024.03.006 names it Indian J Tuberc 2024
Biphasic Medium Using Nicotinamide for Detection of Pyrazinamide Resistance in Mycobacterium tuberculosis. doi:10.3390/antibiotics13060563 Antibiotics (Basel) 2024
Drug Susceptibility and Mutation Profiles in Mycobacterium tuberculosis Isolates from a Tertiary Care Hospital in Kerala, India. doi:10.4269/ajtmh.24-0042 Am J Trop Med Hyg 2024
Identification of positively selected genes in Mycobacterium tuberculosis from southern Xinjiang Uygur autonomous region of China. doi:10.3389/fmicb.2024.1290227 Front Microbiol 2024
Mechanistic insights into the conformational changes and alterations in residual communications due to the mutations in the pncA Gene of Mycobacterium tuberculosis: A computational perspective for effective therapeutic solutions. doi:10.1016/j.compbiolchem.2024.108065 names it Comput Biol Chem 2024
Comparison of targeted next-generation sequencing and the Xpert MTB/RIF assay for detection of Mycobacterium tuberculosis in clinical isolates and sputum specimens. doi:10.1128/spectrum.04098-23 Microbiol Spectr 2024
Concordance of targeted and whole genome sequencing for Mycobacterium tuberculosis genotypic drug susceptibility testing. doi:10.1016/j.diagmicrobio.2024.116249 Diagn Microbiol Infect Dis 2024
Prediction of pyrazinamide resistance in Mycobacterium tuberculosis using structure-based machine-learning approaches. doi:10.1093/jacamr/dlae037 JAC Antimicrob Resist 2024
Rapid detection of multidrug resistance in tuberculosis using nanopore-based targeted next-generation sequencing: a multicenter, double-blind study. doi:10.3389/fmicb.2024.1349715 Front Microbiol 2024
Exploring of pyrazinamidase recombinant activity from PZA-sensitive and resistant Mycobacterium tuberculosis expressed in Escherichia coli BL21 (DE3). doi:10.1590/1519-6984.278911 Braz J Biol 2024
Prevalence, Transmission and Genetic Diversity of Pyrazinamide Resistance Among Multidrug-Resistant Mycobacterium tuberculosis Isolates in Hunan, China. doi:10.2147/IDR.S436161 Infect Drug Resist 2024
Emerging insight of whole genome sequencing coupled with protein structure prediction into the pyrazinamide-resistance signature of Mycobacterium tuberculosis. doi:10.1016/j.ijantimicag.2023.107053 Int J Antimicrob Agents 2024
Free energy landscape and thermodynamics properties of novel mutations in PncA of pyrazinamide resistance isolates of Mycobacterium tuberculosis. doi:10.1080/07391102.2023.2268216 names it J Biomol Struct Dyn 2024
Insights from the molecular mechanism of pyrazinamide to mutated pyrazinamidase linked to the pncA gene in clinical isolates of Mycobacterium tuberculosis. doi:10.1080/07391102.2023.2195002 names it J Biomol Struct Dyn 2024
A precision overview of genomic resistance screening in Ecuadorian isolates of Mycobacterium tuberculosis using web-based bioinformatics tools. doi:10.1371/journal.pone.0294670 PLoS One 2023
Antimicrobial drug resistant features of Mycobacterium tuberculosis associated with treatment failure. doi:10.1371/journal.pone.0293194 PLoS One 2023
Genetic surveillance and outcomes of pyrazinamide and fluoroquinolones-resistant tuberculosis in Taiwan. doi:10.1016/j.jmii.2023.08.013 J Microbiol Immunol Infect 2023
Whole genome sequencing of drug resistance Mycobacterium tuberculosis from extra-pulmonary sites. doi:10.26508/lsa.202302076 Life Sci Alliance 2023
Pharmacokinetic Considerations for Optimizing Inhaled Spray-Dried Pyrazinoic Acid Formulations. doi:10.1021/acs.molpharmaceut.3c00199 Mol Pharm 2023
Surveillance of multidrug-resistant tuberculosis in sub-Saharan Africa through wastewater-based epidemiology. doi:10.1016/j.heliyon.2023.e18302 Heliyon 2023
Drug resistance prediction for Mycobacterium tuberculosis with reference graphs. doi:10.1099/mgen.0.001081 Microb Genom 2023
Deciphering the emerging role of phytocompounds: Implications in the management of drug-resistant tuberculosis and ATDs-induced hepatic damage. doi:10.1016/j.jiph.2023.07.016 J Infect Public Health 2023
pncA Large Deletion is the Characteristic of Pyrazinamide-Resistant Mycobacterium tuberculosis belonging to the East Asian Lineage. doi:10.3947/ic.2023.0037 names it Infect Chemother 2023
Emergence and evolution of drug-resistant Mycobacterium tuberculosis in eastern China: A six-year prospective study. doi:10.1016/j.ygeno.2023.110640 Genomics 2023
Quantitative (1)H Nuclear Magnetic Resonance Assay for the Rapid Detection of Pyrazinamide Resistance in Mycobacterium tuberculosis from Sputum Samples. doi:10.1128/jcm.01522-22 J Clin Microbiol 2023
Pharmacokinetic considerations for optimizing inhaled spray-dried pyrazinoic acid formulations. doi:10.1101/2023.04.01.534965 bioRxiv 2023
Pyrazinamide-resistant Tuberculosis Obscured From Common Targeted Molecular Diagnostics. doi:10.1016/j.drup.2023.100959 Drug Resist Updat 2023
Online Service with Automated Interpretation of Sequencing Data and Prediction of Pyrazinamide Resistance in Mycobacterium tuberculosis. doi:10.1007/s10517-023-05758-6 Bull Exp Biol Med 2023
Bacterial PncA improves diet-induced NAFLD in mice by enabling the transition from nicotinamide to nicotinic acid. doi:10.1038/s42003-023-04613-8 names it Commun Biol 2023
Deciphering the mechanism of resistance by novel double mutations in pncA in Mycobacterium tuberculosis using protein structural graphs (PSG) and structural bioinformatic approaches. doi:10.1016/j.compbiomed.2023.106599 names it Comput Biol Med 2023
The past, present and future of tuberculosis treatment. doi:10.3724/zdxbyxb-2022-0454 Zhejiang Da Xue Xue Bao Yi Xue Ban 2022
Comparative genome analysis reveals high-level drug resistance markers in a clinical isolate of Mycobacterium fortuitum subsp. fortuitum MF GZ001. doi:10.3389/fcimb.2022.1056007 Front Cell Infect Microbiol 2022
Genomic analysis of Mycobacterium tuberculosis variant bovis strains isolated from bovine in the state of Mato Grosso, Brazil. doi:10.3389/fvets.2022.1006090 Front Vet Sci 2022
Structure activity relationship of pyrazinoic acid analogs as potential antimycobacterial agents. doi:10.1016/j.bmc.2022.117046 Bioorg Med Chem 2022
Mutations Associated with Pyrazinamide Resistance in Mycobacterium tuberculosis: A Review and Update. doi:10.1007/s00284-022-03032-y Curr Microbiol 2022
Detection of Mutations in pncA in Mycobacterium tuberculosis Clinical Isolates from Nepal in Association with Pyrazinamide Resistance. doi:10.3390/cimb44090283 names it Curr Issues Mol Biol 2022
Pyrazinamide resistance in rifampicin discordant tuberculosis. doi:10.1371/journal.pone.0274688 PLoS One 2022
Pyrazinamide Resistance and pncA Mutation Profiles in Multidrug Resistant Mycobacterium Tuberculosis. doi:10.2147/IDR.S368444 names it Infect Drug Resist 2022
Prediction of drug resistance by Sanger sequencing of Mycobacterium tuberculosis complex strains isolated from multidrug resistant tuberculosis suspect patients in Ethiopia. doi:10.1371/journal.pone.0271508 PLoS One 2022
Drug resistant Mycobacterium tuberculosis in Oman: resistance-conferring mutations and lineage diversity. doi:10.7717/peerj.13645 PeerJ 2022
[Prevalence and transmission of pyrazinamide-resistant Mycobacterium tuberculosis in Hunan Province,China]. doi:10.3760/cma.j.cn112147-20211219-00904 Zhonghua Jie He He Hu Xi Za Zhi 2022
Intra-host genetic population diversity: Role in emergence and persistence of drug resistance among Mycobacterium tuberculosis complex minor variants. doi:10.1016/j.meegid.2022.105288 Infect Genet Evol 2022
[Investigation of pncA, rpsA and panD Gene Mutations Associated with Resistance in Pyrazinamide-Resistant Mycobacterium tuberculosis Isolates and Spoligotyping]. doi:10.5578/mb.20229801 names it Mikrobiyol Bul 2022
Identification of mutations in rpoB, pncA, embB, and ubiA genes among drug-resistant Mycobacterium tuberculosis clinical isolates from Iran. doi:10.1556/030.2022.01730 names it Acta Microbiol Immunol Hung 2022
Characterization of Fluoroquinolone-Resistant and Multidrug-Resistant Mycobacterium tuberculosis Isolates Using Whole-Genome Sequencing in Tianjin, China. doi:10.2147/IDR.S361635 Infect Drug Resist 2022
Structural and Dynamic Insights into the W68L, L85P, and T87A Mutations of Mycobacterium tuberculosis Inducing Resistance to Pyrazinamide. doi:10.3390/ijerph19031615 Int J Environ Res Public Health 2022
Next-generation sequencing to characterise pyrazinamide resistance in Mycobacterium tuberculosis isolates from two Balkan countries. doi:10.1016/j.jgar.2021.09.019 J Glob Antimicrob Resist 2022
Comparative Performance of Genomic Methods for the Detection of Pyrazinamide Resistance and Heteroresistance in Mycobacterium tuberculosis. doi:10.1128/JCM.01907-21 J Clin Microbiol 2022
The pncA gene mutations of Mycobacterium tuberculosis in multidrug-resistant tuberculosis. doi:10.1002/bab.2278 names it Biotechnol Appl Biochem 2022
Evaluation of PCR pncA-restriction fragment length polymorphism and PCR amplification of genomic regions of difference for the identification of M. bovis strains in lymph nodes cultures. doi:10.4314/ahs.v21i3.4 names it Afr Health Sci 2021
Prevalences of levofloxacin resistance and pncA mutation in isoniazid-resistant Mycobacterium tuberculosis in Hong Kong. doi:10.12809/hkmj208553 names it Hong Kong Med J 2021
Whole Genome Sequencing of Drug Resistant and Drug Susceptible Mycobacterium tuberculosis Isolates From Tigray Region, Ethiopia. doi:10.3389/fmicb.2021.743198 Front Microbiol 2021
Whole genome sequencing reveals large deletions and other loss of function mutations in Mycobacterium tuberculosis drug resistance genes. doi:10.1099/mgen.0.000724 Microb Genom 2021
Wastewater-Based Surveillance of Antibiotic Resistance Genes Associated with Tuberculosis Treatment Regimen in KwaZulu Natal, South Africa. doi:10.3390/antibiotics10111362 Antibiotics (Basel) 2021
The whole-genome sequencing in predicting Mycobacterium tuberculosis drug susceptibility and resistance in Papua, Indonesia. doi:10.1186/s12864-021-08139-3 BMC Genomics 2021
Genetic Diversity and Drug Susceptibility Profiles of Multidrug-Resistant Tuberculosis Strains in Southeast China. doi:10.2147/IDR.S331516 Infect Drug Resist 2021
Structural and Genomic Insights Into Pyrazinamide Resistance in Mycobacterium tuberculosis Underlie Differences Between Ancient and Modern Lineages. doi:10.3389/fmolb.2021.619403 Front Mol Biosci 2021
Phenotypic and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates in Ningbo, China. doi:10.1186/s12879-021-06306-1 BMC Infect Dis 2021
Insights Into Mutations Induced Conformational Changes and Rearrangement of Fe(2+) Ion in pncA Gene of Mycobacterium tuberculosis to Decipher the Mechanism of Resistance to Pyrazinamide. doi:10.3389/fmolb.2021.633365 names it Front Mol Biosci 2021
The 7H11 Agar Medium Supplemented with Calf Bovine Serum for Susceptibility Testing of Mycobacterium tuberculosis Isolates Against Pyrazinamide. doi:10.1089/mdr.2020.0509 Microb Drug Resist 2021
Computational modeling and bioinformatic analyses of functional mutations in drug target genes in Mycobacterium tuberculosis. doi:10.1016/j.csbj.2021.04.034 Comput Struct Biotechnol J 2021
Overcoming the Challenges of Pyrazinamide Susceptibility Testing in Clinical Mycobacterium tuberculosis Isolates. doi:10.1128/AAC.02617-20 Antimicrob Agents Chemother 2021
Molecular epidemiology of Mycobacterium tuberculosis in adult Filipino TB-HIV co-infected patients. doi:10.5588/ijtld.20.0878 Int J Tuberc Lung Dis 2021
Value of routine whole genome sequencing for Mycobacterium tuberculosis drug resistance detection. doi:10.1016/j.ijid.2021.03.033 Int J Infect Dis 2021
Genome analyses of 174 strains of Mycobacterium tuberculosis provide insight into the evolution of drug resistance and reveal potential drug targets. doi:10.1099/mgen.0.000542 Microb Genom 2021
Atypical Genetic Basis of Pyrazinamide Resistance in Monoresistant Mycobacterium tuberculosis. doi:10.1128/AAC.01916-20 Antimicrob Agents Chemother 2021
Synthesis, in vitro antibacterial activity against Mycobacterium tuberculosis, and reverse docking-based target fishing of 1,4-benzoxazin-2-one derivatives. doi:10.1002/ardp.202000199 Arch Pharm (Weinheim) 2021
Prevalence and molecular characterizations of seven additional drug resistance among multidrug-resistant tuberculosis in China: A subsequent study of a national survey. doi:10.1016/j.jinf.2021.02.004 J Infect 2021
Drug resistance gene mutations and treatment outcomes in MDR-TB: A prospective study in Eastern China. doi:10.1371/journal.pntd.0009068 PLoS Negl Trop Dis 2021
A computational perspective on the dynamic behaviour of recurrent drug resistance mutations in the pncA gene from Mycobacterium tuberculosis. doi:10.1039/d0ra09326b names it RSC Adv 2021
An explainable machine learning platform for pyrazinamide resistance prediction and genetic feature identification of Mycobacterium tuberculosis. doi:10.1093/jamia/ocaa233 J Am Med Inform Assoc 2021
Genotypic Resistance of Pyrazinamide but Not Minimum Inhibitory Concentration Is Associated With Longer Time to Sputum Culture Conversion in Patients With Multidrug-resistant Tuberculosis. doi:10.1093/cid/ciaa1509 Clin Infect Dis 2021
The Prospective Synergy of Antitubercular Drugs With NAD Biosynthesis Inhibitors. doi:10.3389/fmicb.2020.634640 Front Microbiol 2020
Characterization of pncA Mutations and Prediction of PZA Resistance in Mycobacterium tuberculosis Clinical Isolates From Chongqing, China. doi:10.3389/fmicb.2020.594171 names it Front Microbiol 2020
Pyrazinamide resistance and pncA mutations in drug resistant Mycobacterium tuberculosis clinical isolates from Myanmar. doi:10.1016/j.tube.2020.102013 names it Tuberculosis (Edinb) 2020
Mechanistic analysis of A46V, H57Y, and D129N in pyrazinamidase associated with pyrazinamide resistance. doi:10.1016/j.sjbs.2020.07.015 Saudi J Biol Sci 2020
Pyrazinamide resistance of novel mutations in pncA and their dynamic behavior. doi:10.1039/d0ra06072k names it RSC Adv 2020
Pyrazinamide Resistance and Mutation Patterns Among Multidrug-Resistant Mycobacterium tuberculosis from Henan Province. doi:10.2147/IDR.S260161 Infect Drug Resist 2020
Colorimetric methods for rapid determination of pyrazinamide resistance. doi:10.4103/ijmy.ijmy_42_20 Int J Mycobacteriol 2020
Prediction of Mycobacterium tuberculosis pyrazinamidase function based on structural stability, physicochemical and geometrical descriptors. doi:10.1371/journal.pone.0235643 PLoS One 2020
Pentacyanoferrate(II) complex of pyridine-4- and pyrazine-2-hydroxamic acid as source of HNO: investigation of anti-tubercular and vasodilation activities. doi:10.1007/s00775-020-01805-z J Biol Inorg Chem 2020
How To Optimally Combine Genotypic and Phenotypic Drug Susceptibility Testing Methods for Pyrazinamide. doi:10.1128/AAC.01003-20 Antimicrob Agents Chemother 2020
Determining the unbinding events and conserved motions associated with the pyrazinamide release due to resistance mutations of Mycobacterium tuberculosis pyrazinamidase. doi:10.1016/j.csbj.2020.05.009 Comput Struct Biotechnol J 2020
Survey of drug resistance associated gene mutations in Mycobacterium tuberculosis, ESKAPE and other bacterial species. doi:10.1038/s41598-020-65766-8 Sci Rep 2020
Genomic signatures of drug resistance in highly resistant Mycobacterium tuberculosis strains of the early ancient sublineage of Beijing genotype in Russia. doi:10.1016/j.ijantimicag.2020.106036 Int J Antimicrob Agents 2020
[Analysis on drug resistance-associated mutations of multi-drug resistant Mycobacterium tuberculosis based on whole-genome sequencing in China]. doi:10.3760/cma.j.cn112338-20191111-00800 Zhonghua Liu Xing Bing Xue Za Zhi 2020
High prevalence of phenotypic pyrazinamide resistance and its association with pncA gene mutations in Mycobacterium tuberculosis isolates from Uganda. doi:10.1371/journal.pone.0232543 names it PLoS One 2020
Detection of drug resistant Mycobacterium tuberculosis by high-throughput sequencing of DNA isolated from acid fast bacilli smears. doi:10.1371/journal.pone.0232343 PLoS One 2020
Gibbs Free Energy Calculation of Mutation in PncA and RpsA Associated With Pyrazinamide Resistance. doi:10.3389/fmolb.2020.00052 names it Front Mol Biosci 2020
Mycobacterium smegmatis msmeg_3314 is involved in pyrazinamide and fluoroquinolones susceptibility via NAD(+)/NADH dysregulation. doi:10.2217/fmb-2019-0071 Future Microbiol 2020
Characterization of katG, inhA, rpoB and pncA in Mycobacterium tuberculosis isolates from MDR-TB risk patients in Thailand. doi:10.3855/jidc.11974 names it J Infect Dev Ctries 2020
Artificial Intelligence and Machine learning based prediction of resistant and susceptible mutations in Mycobacterium tuberculosis. doi:10.1038/s41598-020-62368-2 Sci Rep 2020
Detection of Novel Gene Mutations Associated with Pyrazinamide Resistance in Multidrug-Resistant Mycobacterium tuberculosis Clinical Isolates in Southern China. doi:10.2147/IDR.S230774 Infect Drug Resist 2020
Rapid Pyrazinamide Drug Susceptibility Testing using a Closed-Tube PCR Assay of the Entire pncA gene. doi:10.1038/s41598-020-61286-7 names it Sci Rep 2020
Direct Determination of Pyrazinamide (PZA) Susceptibility by Sputum Microscopic Observation Drug Susceptibility (MODS) Culture at Neutral pH: the MODS-PZA Assay. doi:10.1128/JCM.01165-19 J Clin Microbiol 2020
Management of multidrug-resistant tuberculosis with shorter treatment regimen in Niger: Nationwide programmatic achievements. doi:10.1016/j.rmed.2019.105844 Respir Med 2020
Structure guided prediction of Pyrazinamide resistance mutations in pncA. doi:10.1038/s41598-020-58635-x names it Sci Rep 2020
Molecular identification of mutations conferring resistance to rifampin, isoniazid and pyrazinamide among Mycobacterium tuberculosis isolates from Iran. doi:10.1080/1120009X.2020.1716479 J Chemother 2020
Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China. doi:10.1186/s12879-020-4758-9 BMC Infect Dis 2020
Nicotinamide Limits Replication of Mycobacterium tuberculosis and Bacille Calmette-Guérin Within Macrophages. doi:10.1093/infdis/jiz541 J Infect Dis 2020
Molecular investigation against the resistant mechanism of PncA mutated pyrazinamide resistance and insight into the role of pH environment for pyrazinamide activation. doi:10.1080/07391102.2019.1659854 names it J Biomol Struct Dyn 2020
Structural dynamics behind variants in pyrazinamidase and pyrazinamide resistance. doi:10.1080/07391102.2019.1650113 J Biomol Struct Dyn 2020
Structural Dynamics Behind Clinical Mutants of PncA-Asp12Ala, Pro54Leu, and His57Pro of Mycobacterium tuberculosis Associated With Pyrazinamide Resistance. doi:10.3389/fbioe.2019.00404 names it Front Bioeng Biotechnol 2019
Molecular characterization of multidrug-resistant Mycobacterium tuberculosis (MDR-TB) isolates identifies local transmission of infection in Kuwait, a country with a low incidence of TB and MDR-TB. doi:10.1186/s40001-019-0397-2 Eur J Med Res 2019
Detection of Mutations in Mycobacterium tuberculosis pncA Gene by Modified High-Resolution Melting Curve Analysis of PCR Products. doi:10.1007/s10517-019-04688-6 names it Bull Exp Biol Med 2019
Improved Resistance Prediction in Mycobacterium tuberculosis by Better Handling of Insertions and Deletions, Premature Stop Codons, and Filtering of Non-informative Sites. doi:10.3389/fmicb.2019.02464 Front Microbiol 2019
Resistance To First-Line Antituberculosis Drugs And Prevalence Of pncA Mutations In Clinical Isolates Of Mycobacterium tuberculosis From Zunyi, Guizhou Province Of China. doi:10.2147/IDR.S222943 names it Infect Drug Resist 2019
Whole genome sequencing, analyses of drug resistance-conferring mutations, and correlation with transmission of Mycobacterium tuberculosis carrying katG-S315T in Hanoi, Vietnam. doi:10.1038/s41598-019-51812-7 Sci Rep 2019
Antibiotic resistance of Mycobacterium tuberculosis complex in Africa: A systematic review of current reports of molecular epidemiology, mechanisms and diagnostics. doi:10.1016/j.jinf.2019.10.006 J Infect 2019
Whole genome sequencing of drug resistant Mycobacterium tuberculosis isolates from a high burden tuberculosis region of North West Pakistan. doi:10.1038/s41598-019-51562-6 Sci Rep 2019
Spoligotyping with pncA sequencing strategy conferring the transmission of multidrug-resistant tuberculosis in Egypt. doi:10.4103/ijmy.ijmy_111_19 names it Int J Mycobacteriol 2019
Retrospective Analysis of Archived Pyrazinamide Resistant Mycobacterium tuberculosis Complex Isolates from Uganda-Evidence of Interspecies Transmission. doi:10.3390/microorganisms7080221 Microorganisms 2019
Direct Detection of Pyrazinamide Resistance in Mycobacterium tuberculosis by Use of pncA PCR Sequencing. doi:10.1128/JCM.00145-19 names it J Clin Microbiol 2019
WGS more accurately predicts susceptibility of Mycobacterium tuberculosis to first-line drugs than phenotypic testing. doi:10.1093/jac/dkz215 J Antimicrob Chemother 2019
Structural and free energy landscape of novel mutations in ribosomal protein S1 (rpsA) associated with pyrazinamide resistance. doi:10.1038/s41598-019-44013-9 Sci Rep 2019
Overcoming the pitfalls of automatic interpretation of whole genome sequencing data by online tools for the prediction of pyrazinamide resistance in Mycobacterium tuberculosis. doi:10.1371/journal.pone.0212798 PLoS One 2019
Exploring the Pyrazinamide Drug Resistance Mechanism of Clinical Mutants T370P and W403G in Ribosomal Protein S1 of Mycobacterium tuberculosis. doi:10.1021/acs.jcim.8b00956 J Chem Inf Model 2019
Rapid microarray-based assay for detection of pyrazinamide resistant Mycobacterium tuberculosis. doi:10.1016/j.diagmicrobio.2018.12.011 Diagn Microbiol Infect Dis 2019
Underestimated pyrazinamide resistance may compromise outcomes of pyrazinamide containing regimens for treatment of drug susceptible and multi-drug-resistant tuberculosis in Tanzania. doi:10.1186/s12879-019-3757-1 BMC Infect Dis 2019
Pyrazinamide resistance and mutations in pncA among isolates of Mycobacterium tuberculosis from Khyber Pakhtunkhwa, Pakistan. doi:10.1186/s12879-019-3764-2 names it BMC Infect Dis 2019
Conventional and molecular determination of drug resistance in Mycobacterium tuberculosis and Mycobacterium bovis isolates in cattle. doi:10.1016/j.tube.2018.12.005 Tuberculosis (Edinb) 2019
Application of next-generation sequencing to detect variants of drug-resistant Mycobacterium tuberculosis: genotype-phenotype correlation. doi:10.1186/s12941-018-0300-y Ann Clin Microbiol Antimicrob 2019
Characterization of novel Mycobacterium tuberculosis pncA gene mutations in clinical isolates from the Ukraine. doi:10.1016/j.diagmicrobio.2018.10.018 names it Diagn Microbiol Infect Dis 2019
Introducing molecular testing of pyrazinamide susceptibility improves multidrug-resistant tuberculosis treatment outcomes: a prospective cohort study. doi:10.1183/13993003.01770-2018 Eur Respir J 2019
Pyrazinamide resistance and mutations L19R, R140H, and E144K in Pyrazinamidase of Mycobacterium tuberculosis. doi:10.1002/jcb.27989 J Cell Biochem 2019
Insights into the Mechanisms of the Pyrazinamide Resistance of Three Pyrazinamidase Mutants N11K, P69T, and D126N. doi:10.1021/acs.jcim.8b00525 J Chem Inf Model 2019
A Diagnostic Algorithm To Investigate Pyrazinamide and Ethambutol Resistance in Rifampin-Resistant Mycobacterium tuberculosis Isolates in a Low-Incidence Setting. doi:10.1128/AAC.01798-18 Antimicrob Agents Chemother 2019
pncA gene mutations in reporting pyrazinamide resistance among the MDR-TB suspects. doi:10.1016/j.meegid.2018.11.012 names it Infect Genet Evol 2019
MODS-Wayne, a Colorimetric Adaptation of the Microscopic-Observation Drug Susceptibility (MODS) Assay for Detection of Mycobacterium tuberculosis Pyrazinamide Resistance from Sputum Samples. doi:10.1128/JCM.01162-18 J Clin Microbiol 2019
Use of whole-genome sequencing to predict Mycobacterium tuberculosis drug resistance in Indonesia. doi:10.1016/j.jgar.2018.08.018 J Glob Antimicrob Resist 2019
Insight into novel clinical mutants of RpsA-S324F, E325K, and G341R of Mycobacterium tuberculosis associated with pyrazinamide resistance. doi:10.1016/j.csbj.2018.09.004 Comput Struct Biotechnol J 2018
Whole-genome sequencing and single nucleotide polymorphisms in multidrug-resistant clinical isolates of Mycobacterium tuberculosis from the Philippines. doi:10.1016/j.jgar.2018.08.009 J Glob Antimicrob Resist 2018
Characterization of pncA mutations in multi-drug and pyrazinamide resistant Mycobacterium tuberculosis isolates cultured from Queensland migrants and Papua New Guinea residents. doi:10.1016/j.tube.2018.06.006 names it Tuberculosis (Edinb) 2018
Is sequencing better than phenotypic tests for the detection of pyrazinamide resistance? doi:10.5588/ijtld.17.0715 Int J Tuberc Lung Dis 2018
Computational discovery of potent drugs to improve the treatment of pyrazinamide resistant Mycobacterium tuberculosis mutants. doi:10.1002/jcb.27033 J Cell Biochem 2018
Author Correction: Analysis of mutations in pncA reveals non-overlapping patterns among various lineages of Mycobacterium tuberculosis. doi:10.1038/s41598-018-25809-7 names it Sci Rep 2018
Analysis of a Novel pncA Mutation for Susceptibility to Pyrazinamide Therapy. doi:10.1164/rccm.201712-2572LE names it Am J Respir Crit Care Med 2018
Novel Mutations in pncA Gene of Pyrazinamide Resistant Clinical Isolates of Mycobacterium tuberculosis. doi:10.3390/scipharm86020015 names it Sci Pharm 2018
Determining Genotypic Drug Resistance by Ion Semiconductor Sequencing With the Ion AmpliSeq™ TB Panel in Multidrug-Resistant Mycobacterium tuberculosis Isolates. doi:10.3343/alm.2018.38.4.316 Ann Lab Med 2018
Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study. doi:10.1016/S1473-3099(18)30073-2 Lancet Infect Dis 2018
Genotypic characterization of pyrazinamide resistance in Mycobacterium tuberculosis isolated from Lusaka, Zambia. doi:10.1016/j.tube.2017.12.007 Tuberculosis (Edinb) 2018
Analysis of mutations in pncA reveals non-overlapping patterns among various lineages of Mycobacterium tuberculosis. doi:10.1038/s41598-018-22883-9 names it Sci Rep 2018
Estimation of pyrazinamidase activity using a cell-free In vitro synthesis of pnca and its association with pyrazinamide susceptibility in Mycobacterium tuberculosis. doi:10.4103/ijmy.ijmy_187_17 names it Int J Mycobacteriol 2018
Multi- and Extensively Drug Resistant Mycobacterium tuberculosis in South Africa: a Molecular Analysis of Historical Isolates. doi:10.1128/JCM.01214-17 J Clin Microbiol 2018
Alarming levels of multidrug-resistant tuberculosis in Ukraine: results from the first national survey. doi:10.5588/ijtld.17.0254 Int J Tuberc Lung Dis 2018
Phenotypic and genotypic characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis clinical isolates in Hangzhou, China. doi:10.1016/j.cmi.2017.12.012 Clin Microbiol Infect 2018
Pyrazinamide Resistance among Multidrug-Resistant Mycobacterium tuberculosis Clinical Isolates in Myanmar. doi:10.1128/AAC.01984-17 Antimicrob Agents Chemother 2018
Molecular drug resistance profiles of Mycobacterium tuberculosis from sputum specimens using ion semiconductor sequencing. doi:10.1016/j.mimet.2017.12.003 J Microbiol Methods 2018
Detection of Mycobacterium tuberculosis pncA Mutations by the Nipro Genoscholar PZA-TB II Assay Compared to Conventional Sequencing. doi:10.1128/AAC.01871-17 names it Antimicrob Agents Chemother 2018
Role of pncA gene mutations W68R and W68G in pyrazinamide resistance. doi:10.1002/jcb.26420 names it J Cell Biochem 2018
Evaluation of a novel line probe assay to detect resistance to pyrazinamide, a key drug used for tuberculosis treatment. doi:10.1016/j.cmi.2017.05.026 Clin Microbiol Infect 2018
Mutation analysis for detection of drug resistance in mycobacterium tuberculosis isolates from Khyber Pakhtunkhwa, Pakistan. J Pak Med Assoc 2017
Prevalence and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Southern China. doi:10.1186/s12879-017-2761-6 BMC Infect Dis 2017
Half of rifampicin-resistant Mycobacterium tuberculosis complex isolated from tuberculosis patients in Sub-Saharan Africa have concomitant resistance to pyrazinamide. doi:10.1371/journal.pone.0187211 PLoS One 2017
A multiple genome analysis of Mycobacterium tuberculosis reveals specific novel genes and mutations associated with pyrazinamide resistance. doi:10.1186/s12864-017-4146-z BMC Genomics 2017
Molecular analysis of pyrazinamide resistance in Mycobacterium tuberculosis in Vietnam highlights the high rate of pyrazinamide resistance-associated mutations in clinical isolates. doi:10.1038/emi.2017.73 Emerg Microbes Infect 2017
A comprehensive characterization of PncA polymorphisms that confer resistance to pyrazinamide. doi:10.1038/s41467-017-00721-2 names it Nat Commun 2017
Update of Antitubercular Prodrugs from a Molecular Perspective: Mechanisms of Action, Bioactivation Pathways, and Associated Resistance. doi:10.1002/cmdc.201700424 ChemMedChem 2017
Improved Bactec MGIT 960 Pyrazinamide Test Decreases Detection of False Mycobacterium tuberculosis Pyrazinamide Resistance. doi:10.1128/JCM.01437-17 J Clin Microbiol 2017
In Silico Prediction of Antibiotic Resistance in Mycobacterium ulcerans Agy99 through Whole Genome Sequence Analysis. doi:10.4269/ajtmh.16-0478 Am J Trop Med Hyg 2017
Pyrazinamide resistance-conferring mutations in pncA and the transmission of multidrug resistant TB in Georgia. doi:10.1186/s12879-017-2594-3 names it BMC Infect Dis 2017
A Multinational Analysis of Mutations and Heterogeneity in PZase, RpsA, and PanD Associated with Pyrazinamide Resistance in M/XDR Mycobacterium tuberculosis. doi:10.1038/s41598-017-03452-y Sci Rep 2017
Pyrazinamide Susceptibility and pncA Mutation Profiles of Mycobacterium tuberculosis among Multidrug-Resistant Tuberculosis Patients in Bangladesh. doi:10.1128/AAC.00511-17 names it Antimicrob Agents Chemother 2017
Screening mutations in drug-resistant Mycobacterium tuberculosis strains in Yunnan, China. doi:10.1016/j.jiph.2017.04.008 J Infect Public Health 2017
Identification of Novel Efflux Proteins Rv0191, Rv3756c, Rv3008, and Rv1667c Involved in Pyrazinamide Resistance in Mycobacterium tuberculosis. doi:10.1128/AAC.00940-17 Antimicrob Agents Chemother 2017
Characterization of pyrazinamide resistance in consecutive multidrug-resistant mycobacterium tuberculosis isolates in sweden between 2003 and 2015. doi:10.4103/ijmy.ijmy_23_17 Int J Mycobacteriol 2017
Prevalence and extent of heteroresistance by next generation sequencing of multidrug-resistant tuberculosis. doi:10.1371/journal.pone.0176522 PLoS One 2017
Performance of TaqMan array card to detect TB drug resistance on direct specimens. doi:10.1371/journal.pone.0177167 PLoS One 2017
Detection of pyrazinamide resistance of Mycobacterium tuberculosis using nicotinamide as a surrogate. doi:10.1016/j.cmi.2017.03.028 Clin Microbiol Infect 2017
Non-pncA Gene-Mutated but Pyrazinamide-Resistant Mycobacterium tuberculosis: Why Is That? doi:10.1128/JCM.02532-16 names it J Clin Microbiol 2017
pncA Gene Mutations Associated with Pyrazinamide Resistance in Drug-Resistant Tuberculosis, South Africa and Georgia. doi:10.3201/eid2303.161034 names it Emerg Infect Dis 2017
FIND Tuberculosis Strain Bank: a Resource for Researchers and Developers Working on Tests To Detect Mycobacterium tuberculosis and Related Drug Resistance. doi:10.1128/JCM.01662-16 J Clin Microbiol 2017
pncA mutations are associated with slower sputum conversion during standard treatment of multidrug-resistant tuberculosis. doi:10.1016/j.ijantimicag.2016.10.012 names it Int J Antimicrob Agents 2017
Long-Chain Fatty Acyl Coenzyme A Ligase FadD2 Mediates Intrinsic Pyrazinamide Resistance in Mycobacterium tuberculosis. doi:10.1128/AAC.02130-16 Antimicrob Agents Chemother 2017
Insights into Pyrazinamidase and DNA Gyrase Protein Structures in Resistant and Susceptible Clinical Isolates of Mycobacterium tuberculosis. Tanaffos 2016
New insights into the mechanism of action of pyrazinamide, implications for susceptibility testing, and future regimens. doi:10.1016/j.ijmyco.2016.08.009 Int J Mycobacteriol 2016
The majority of patients with multidrug-resistant tuberculosis in Sub-Saharan Africa present a concomitant resistance to pyrazinamide. doi:10.1016/j.ijmyco.2016.10.015 Int J Mycobacteriol 2016
Best approaches to drug-resistance surveillance at the country level. doi:10.1016/j.ijmyco.2016.09.010 Int J Mycobacteriol 2016
Impact of genotypic and phenotypic resistance to second-line anti-tuberculosis drugs on treatment outcomes in multidrug-resistant tuberculosis in China. doi:10.1016/j.ijmyco.2016.11.007 Int J Mycobacteriol 2016
Pyrazinamide susceptibility testing: proposed new standard with the BACTECTM MGITTM 960 system. doi:10.5588/ijtld.16.0360 Int J Tuberc Lung Dis 2016
Detecting Mutations in the Mycobacterium tuberculosis Pyrazinamidase Gene pncA to Improve Infection Control and Decrease Drug Resistance Rates in Human Immunodeficiency Virus Coinfection. doi:10.4269/ajtmh.15-0711 names it Am J Trop Med Hyg 2016
Mechanisms of first-line antimicrobial resistance in multi-drug and extensively drug resistant strains of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa. doi:10.1186/s12879-016-1906-3 BMC Infect Dis 2016
Pyrazinamide Resistance Assays and Two-Month Sputum Culture Status in Patients with Multidrug-Resistant Tuberculosis. doi:10.1128/AAC.00632-16 Antimicrob Agents Chemother 2016
Genotypic characterization of drug resistant Mycobacterium tuberculosis in Quebec, 2002-2012. doi:10.1186/s12866-016-0786-4 BMC Microbiol 2016
Prevalence of pyrazinamide resistance across the spectrum of drug resistant phenotypes of Mycobacterium tuberculosis. doi:10.1016/j.tube.2016.05.003 Tuberculosis (Edinb) 2016
A quantitative adaptation of the Wayne test for pyrazinamide resistance. doi:10.1016/j.tube.2016.03.011 Tuberculosis (Edinb) 2016
Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project. doi:10.1016/S1473-3099(16)30190-6 Lancet Infect Dis 2016
Multicenter Study of the Emergence and Genetic Characteristics of Pyrazinamide-Resistant Tuberculosis in China. doi:10.1128/AAC.02687-15 Antimicrob Agents Chemother 2016
Prevalence and transmission of pyrazinamide resistant Mycobacterium tuberculosis in China. doi:10.1016/j.tube.2016.02.008 Tuberculosis (Edinb) 2016
High Systemic Exposure of Pyrazinoic Acid Has Limited Antituberculosis Activity in Murine and Rabbit Models of Tuberculosis. doi:10.1128/AAC.03085-15 Antimicrob Agents Chemother 2016
Pyrazinamide resistance among multidrug-resistant tuberculosis clinical isolates in a national referral center of China and its correlations with pncA, rpsA, and panD gene mutations. doi:10.1016/j.diagmicrobio.2015.10.017 names it Diagn Microbiol Infect Dis 2016
A Novel Molecular Strategy for Surveillance of Multidrug Resistant Tuberculosis in High Burden Settings. doi:10.1371/journal.pone.0146106 PLoS One 2016
The draft genome of Mycobacterium aurum, a potential model organism for investigating drugs against Mycobacterium tuberculosis and Mycobacterium leprae. doi:10.1016/j.ijmyco.2015.05.001 Int J Mycobacteriol 2015
Genome sequence comparisons of serial multi-drug-resistant Mycobacterium tuberculosis isolates over 21 years of infection in a single patient. doi:10.1099/mgen.0.000037 Microb Genom 2015
Evolution of Extensively Drug-Resistant Tuberculosis over Four Decades: Whole Genome Sequencing and Dating Analysis of Mycobacterium tuberculosis Isolates from KwaZulu-Natal. doi:10.1371/journal.pmed.1001880 PLoS Med 2015
Improved Detection by Next-Generation Sequencing of Pyrazinamide Resistance in Mycobacterium tuberculosis Isolates. doi:10.1128/JCM.01179-15 J Clin Microbiol 2015
Uncoupling Environmental pH and Intrabacterial Acidification from Pyrazinamide Susceptibility in Mycobacterium tuberculosis. doi:10.1128/AAC.00967-15 Antimicrob Agents Chemother 2015
Mycobacterium tuberculosis pncA Polymorphisms That Do Not Confer Pyrazinamide Resistance at a Breakpoint Concentration of 100 Micrograms per Milliliter in MGIT. doi:10.1128/JCM.01001-15 names it J Clin Microbiol 2015
A Global Perspective on Pyrazinamide Resistance: Systematic Review and Meta-Analysis. doi:10.1371/journal.pone.0133869 PLoS One 2015
Epidemiologic Correlates of Pyrazinamide-Resistant Mycobacterium tuberculosis in New York City. doi:10.1128/AAC.00764-15 Antimicrob Agents Chemother 2015
Systematic review of mutations in pyrazinamidase associated with pyrazinamide resistance in Mycobacterium tuberculosis clinical isolates. doi:10.1128/AAC.00204-15 Antimicrob Agents Chemother 2015
Resistance to pyrazinamide in Russian Mycobacterium tuberculosis isolates: pncA sequencing versus Bactec MGIT 960. doi:10.1016/j.tube.2015.05.013 names it Tuberculosis (Edinb) 2015
Genome sequencing reveals novel deletions associated with secondary resistance to pyrazinamide in MDR Mycobacterium tuberculosis. doi:10.1093/jac/dkv128 J Antimicrob Chemother 2015
Biochemical Characterization and Computational Identification of Mycobacterium tuberculosis Pyrazinamidase in Some Pyrazinamide-Resistant Isolates of Iran. doi:10.1007/s10930-015-9610-5 Protein J 2015
The indirect microscopic observation drug susceptibility assay demonstrated high concordance with the indirect MGIT method for pyrazinamide susceptibility testing. doi:10.1093/jac/dkv112 J Antimicrob Chemother 2015
Pyrazinamide resistance in Mycobacterium tuberculosis arises after rifampicin and fluoroquinolone resistance. doi:10.5588/ijtld.14.0768 Int J Tuberc Lung Dis 2015
Pyrazinamide: the importance of uncovering the mechanisms of action in mycobacteria. doi:10.1586/14787210.2015.1021784 Expert Rev Anti Infect Ther 2015
Whole genome sequencing based characterization of extensively drug-resistant Mycobacterium tuberculosis isolates from Pakistan. doi:10.1371/journal.pone.0117771 PLoS One 2015
Integrated microfluidic card with TaqMan probes and high-resolution melt analysis to detect tuberculosis drug resistance mutations across 10 genes. doi:10.1128/mBio.02273-14 mBio 2015
Mechanistic analysis elucidating the relationship between Lys96 mutation in Mycobacterium tuberculosis pyrazinamidase enzyme and pyrazinamide susceptibility. doi:10.1186/1471-2164-16-S2-S14 BMC Genomics 2015
Phenotypic and genotypic characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates in Zhejiang, China. doi:10.1128/AAC.04541-14 Antimicrob Agents Chemother 2015
Mutations in the pncA and rpsA genes among 77 Mycobacterium tuberculosis isolates in Kazakhstan. doi:10.5588/ijtld.14.0305 names it Int J Tuberc Lung Dis 2015
Multiple drug-susceptibility screening in Mycobacterium bovis: new nucleotide polymorphisms in the embB gene among ethambutol susceptible strains. doi:10.1016/j.ijid.2014.12.043 Int J Infect Dis 2015
Mechanisms of Pyrazinamide Action and Resistance. doi:10.1128/microbiolspec.MGM2-0023-2013 Microbiol Spectr 2014
Aspartate decarboxylase (PanD) as a new target of pyrazinamide in Mycobacterium tuberculosis. doi:10.1038/emi.2014.61 Emerg Microbes Infect 2014
Multiplex-PCR for differentiation of Mycobacterium bovis from Mycobacterium tuberculosis complex. doi:10.1590/s1517-83822014000300012 Braz J Microbiol 2014
Mycobacterium tuberculosis pyrazinamide resistance determinants: a multicenter study. doi:10.1128/mBio.01819-14 mBio 2014
Rapid sequencing of the Mycobacterium tuberculosis pncA gene for detection of pyrazinamide susceptibility. doi:10.1128/JCM.02438-14 names it J Clin Microbiol 2014
Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates from Korea and analysis of the correlation between the mutations and pyrazinamidase activity. doi:10.1007/s11274-014-1706-0 names it World J Microbiol Biotechnol 2014
Evaluation of a biphasic media assay for pyrazinamide drug susceptibility testing of Mycobacterium tuberculosis. doi:10.1093/jac/dku230 J Antimicrob Chemother 2014
Outbreak of pyrazinamide-monoresistant tuberculosis identified using genotype cluster and social media analysis. doi:10.5588/ijtld.13.0663 Int J Tuberc Lung Dis 2014
Rapid diagnosis of pyrazinamide-resistant multidrug-resistant tuberculosis using a molecular-based diagnostic algorithm. doi:10.1111/1469-0691.12696 Clin Microbiol Infect 2014
Association between pncA gene mutations, pyrazinamidase activity, and pyrazinamide susceptibility testing in Mycobacterium tuberculosis. doi:10.1128/AAC.02394-14 names it Antimicrob Agents Chemother 2014
Prevalence and molecular characteristics of drug-resistant Mycobacterium tuberculosis in Hunan, China. doi:10.1128/AAC.02426-14 Antimicrob Agents Chemother 2014
MUBII-TB-DB: a database of mutations associated with antibiotic resistance in Mycobacterium tuberculosis. doi:10.1186/1471-2105-15-107 BMC Bioinformatics 2014
Characterization of the etiological agents of tuberculous lymphadenitis in Dera Woreda, North Showa, Ethiopia. Ethiop Med J 2014
Characterisation of pyrazinamide-resistant Mycobacterium tuberculosis strains isolated in Poland and Germany. doi:10.5588/ijtld.13.0457 Int J Tuberc Lung Dis 2014
Evidence of Clonal Expansion in the Genome of a Multidrug-Resistant Mycobacterium tuberculosis Clinical Isolate from Peru. doi:10.1128/genomeA.00089-14 Genome Announc 2014
Pyrazinamide susceptibility testing of Mycobacterium tuberculosis by high resolution melt analysis. doi:10.1016/j.tube.2013.10.006 Tuberculosis (Edinb) 2014
Rapid detection of Mycobacterium tuberculosis and pyrazinamide susceptibility related to pncA mutations in sputum specimens through an integrated gene-to-protein function approach. doi:10.1128/JCM.02285-13 names it J Clin Microbiol 2014
Role of pncA and rpsA gene sequencing in detection of pyrazinamide resistance in Mycobacterium tuberculosis isolates from southern China. doi:10.1128/JCM.01903-13 names it J Clin Microbiol 2014
Drug resistance mechanism of PncA in Mycobacterium tuberculosis. doi:10.1080/07391102.2012.759885 names it J Biomol Struct Dyn 2014
Multidrug-resistant Myobacterium tuberculosis caused by the Beijing genotype and a specific T1 genotype clone (SIT No. 266) is widely transmitted in Minsk. doi:10.1016/j.ijmyco.2013.08.001 Int J Mycobacteriol 2013
Performance of the microscopic observation drug susceptibility assay in pyrazinamide susceptibility testing for Mycobacterium tuberculosis. Chin Med J (Engl) 2013
Rapid detection of pyrazinamide resistant Mycobacterium tuberculosis by high resolution melting curve analysis. J Med Assoc Thai 2013
Proficiency of drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide: the Swedish experience. doi:10.5588/ijtld.13.0195 Int J Tuberc Lung Dis 2013
Primary multidrug-resistant Mycobacterium tuberculosis in 2 regions, Eastern Siberia, Russian Federation. doi:10.3201/eid1910.121108 Emerg Infect Dis 2013
Application of quantitative second-line drug susceptibility testing at a multidrug-resistant tuberculosis hospital in Tanzania. doi:10.1186/1471-2334-13-432 BMC Infect Dis 2013
pncA gene expression and prediction factors on pyrazinamide resistance in Mycobacterium tuberculosis. doi:10.1016/j.tube.2013.03.005 names it Tuberculosis (Edinb) 2013
[Detection of pncA mutation associated with pyrazinamide resistance in Mycobacterium tuberculosis by high-resolution melting cure analysis]. names it Zhonghua Jie He He Hu Xi Za Zhi 2013
Tuberculosis patients co-infected with Mycobacterium bovis and Mycobacterium tuberculosis in an urban area of Brazil. doi:10.1590/S0074-02762013000300010 Mem Inst Oswaldo Cruz 2013
Mycobacterium tuberculosis isolates from Rio de Janeiro reveal unusually low correlation between pyrazinamide resistance and mutations in the pncA gene. doi:10.1016/j.meegid.2013.06.008 names it Infect Genet Evol 2013
Mutations in panD encoding aspartate decarboxylase are associated with pyrazinamide resistance in Mycobacterium tuberculosis. doi:10.1038/emi.2013.38 Emerg Microbes Infect 2013
Characterization of mutations in multi- and extensive drug resistance among strains of Mycobacterium tuberculosis clinical isolates in Republic of Korea. doi:10.1016/j.diagmicrobio.2013.02.035 Diagn Microbiol Infect Dis 2013
Mycobacterium canettii is intrinsically resistant to both pyrazinamide and pyrazinoic acid. doi:10.1093/jac/dkt042 J Antimicrob Chemother 2013
Density functional and molecular docking studies towards investigating the role of single-wall carbon nanotubes as nanocarrier for loading and delivery of pyrazinamide antitubercular drug onto pncA protein. doi:10.1007/s10822-013-9638-6 names it J Comput Aided Mol Des 2013
Evaluation of methods for testing the susceptibility of clinical Mycobacterium tuberculosis isolates to pyrazinamide. doi:10.1128/JCM.03197-12 J Clin Microbiol 2013
Base-calling algorithm with vocabulary (BCV) method for analyzing population sequencing chromatograms. doi:10.1371/journal.pone.0054835 PLoS One 2013
Characterization of pncA gene mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates from Mexico. doi:10.1016/j.meegid.2012.12.013 names it Infect Genet Evol 2013
Mechanisms of Pyrazinamide Action and Resistance. doi:10.1128/microbiolspec.MGM2-0023-2013 Microbiol Spectr 2013
Prevention of false resistance results obtained in testing the susceptibility of Mycobacterium tuberculosis to pyrazinamide with the Bactec MGIT 960 system using a reduced inoculum. doi:10.1128/JCM.01838-12 J Clin Microbiol 2013
Phenotypic and genotypic characteristics of drug resistance in Mycobacterium tuberculosis isolates from pediatric population of Chennai, India. doi:10.4103/0255-0857.103761 Indian J Med Microbiol 2012
pncA Mutations in the Specimens from Extrapulmonary Tuberculosis. doi:10.4046/trd.2012.72.6.475 names it Tuberc Respir Dis (Seoul) 2012
Next-generation ion torrent sequencing of drug resistance mutations in Mycobacterium tuberculosis strains. doi:10.1128/JCM.01893-12 J Clin Microbiol 2012
Gene sequencing for routine verification of pyrazinamide resistance in Mycobacterium tuberculosis: a role for pncA but not rpsA. doi:10.1128/JCM.00620-12 names it J Clin Microbiol 2012
[Characteristics of pncA gene in multidrug-resistant Mycobacterium tuberculosis isolates and its correlation with drug resistance to pyrazinamide]. names it Zhonghua Yu Fang Yi Xue Za Zhi 2012
Systematic analysis of pyrazinamide-resistant spontaneous mutants and clinical isolates of Mycobacterium tuberculosis. doi:10.1128/AAC.05385-11 Antimicrob Agents Chemother 2012
Molecular dynamics simulations suggest ligand's binding to nicotinamidase/pyrazinamidase. doi:10.1371/journal.pone.0039546 PLoS One 2012
'Z(S)-MDR-TB' versus 'Z(R)-MDR-TB': improving treatment of MDR-TB by identifying pyrazinamide susceptibility. doi:10.1038/emi.2012.18 Emerg Microbes Infect 2012
Sequence analysis for detection of first-line drug resistance in Mycobacterium tuberculosis strains from a high-incidence setting. doi:10.1186/1471-2180-12-90 BMC Microbiol 2012
Filterable forms and L-forms of Mycobacterium bovis BCG: impact for live vaccine features. doi:10.4161/hv.19698 Hum Vaccin Immunother 2012
Drug resistance of Mycobacterium tuberculosis strains in southern Brazil. doi:10.1590/s0037-86822012000100018 Rev Soc Bras Med Trop 2012
Detection and identification of Mycobacterium tuberculosis and Mycobacterium bovis from clinical species using DNA microarrays. doi:10.1177/1040638711417141 J Vet Diagn Invest 2012
Pyrazinamide: a frontline drug used for tuberculosis. Molecular mechanism of action resolved after 50 years? doi:10.1002/cmdc.201100587 ChemMedChem 2012
Fluoroquinolone and pyrazinamide resistance in multidrug-resistant tuberculosis. doi:10.5588/ijtld.11.0266 Int J Tuberc Lung Dis 2012
Patterns of pncA mutations in drug-resistant Mycobacterium tuberculosis isolated from patients in South Korea. doi:10.5588/ijtld.10.0739 names it Int J Tuberc Lung Dis 2012
Reevaluation of the critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide using wild-type MIC distributions and pncA gene sequencing. doi:10.1128/AAC.05894-11 names it Antimicrob Agents Chemother 2012
Validation of pncA gene sequencing in combination with the mycobacterial growth indicator tube method to test susceptibility of Mycobacterium tuberculosis to pyrazinamide. doi:10.1128/JCM.05435-11 names it J Clin Microbiol 2012
Pyrazinoic acid efflux rate in Mycobacterium tuberculosis is a better proxy of pyrazinamide resistance. doi:10.1016/j.tube.2011.09.002 Tuberculosis (Edinb) 2012
Rapid colorimetric testing for pyrazinamide susceptibility of M. tuberculosis by a PCR-based in-vitro synthesized pyrazinamidase method. doi:10.1371/journal.pone.0027654 PLoS One 2011
Characteristics of pncA mutations in multidrug-resistant tuberculosis in Taiwan. doi:10.1186/1471-2334-11-240 names it BMC Infect Dis 2011
Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. doi:10.1126/science.1208813 Science 2011
Structure-Activity relationship in mutated pyrazinamidases from Mycobacterium tuberculosis. doi:10.6026/97320630006335 Bioinformation 2011
Pyrazinamide susceptibility testing in Mycobacterium tuberculosis: a systematic review with meta-analyses. doi:10.1128/AAC.00630-11 Antimicrob Agents Chemother 2011
The Guinea-Bissau family of Mycobacterium tuberculosis complex revisited. doi:10.1371/journal.pone.0018601 PLoS One 2011
Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. doi:10.1128/AAC.01550-10 Antimicrob Agents Chemother 2011
Crystal structure of the pyrazinamidase of Mycobacterium tuberculosis: insights into natural and acquired resistance to pyrazinamide. doi:10.1371/journal.pone.0015785 PLoS One 2011
Kinetics and inhibition of nicotinamidase from Mycobacterium tuberculosis. doi:10.1021/bi1011157 Biochemistry 2010
Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy. doi:10.1128/AAC.00529-10 Antimicrob Agents Chemother 2010
Surveillance of pyrazinamide susceptibility among multidrug-resistant Mycobacterium tuberculosis isolates from Siriraj Hospital, Thailand. doi:10.1186/1471-2180-10-223 BMC Microbiol 2010
Molecular epidemiological study of pyrazinamide-resistance in clinical isolates of mycobacterium tuberculosis from South India. doi:10.3390/ijms11072670 Int J Mol Sci 2010
Evaluation of colorimetric methods using nicotinamide for rapid detection of pyrazinamide resistance in Mycobacterium tuberculosis. doi:10.1128/JCM.00311-10 J Clin Microbiol 2010
Rapid identification of multidrug-resistant tuberculosis isolates in treatment failure or relapse patients in Bangui, Central African Republic. Int J Tuberc Lung Dis 2010
The near future: improving the activity of rifamycins and pyrazinamide. doi:10.1016/j.tube.2010.03.005 Tuberculosis (Edinb) 2010
NAD+ auxotrophy is bacteriocidal for the tubercle bacilli. doi:10.1111/j.1365-2958.2010.07099.x Mol Microbiol 2010
Determination of the susceptibility of Mycobacterium tuberculosis to pyrazinamide in liquid and solid media assessed by a colorimetric nitrate reductase assay. doi:10.1093/jac/dkp506 J Antimicrob Chemother 2010
Peruvian and globally reported amino acid substitutions on the Mycobacterium tuberculosis pyrazinamidase suggest a conserved pattern of mutations associated to pyrazinamide resistance. doi:10.1016/j.meegid.2009.11.016 Infect Genet Evol 2010
Potential for erroneous results indicating resistance when using the Bactec MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide. doi:10.1128/JCM.01775-09 J Clin Microbiol 2010
Pyrazinamide resistance in multidrug-resistant Mycobacterium tuberculosis isolates in Japan. doi:10.1111/j.1469-0691.2009.03078.x Clin Microbiol Infect 2010
Clinical efficacy of direct DNA sequencing analysis on sputum specimens for early detection of drug-resistant Mycobacterium tuberculosis in a clinical setting. doi:10.1378/chest.09-0150 Chest 2010
Insight to pyrazinamide resistance in Mycobacterium tuberculosis by molecular docking. doi:10.6026/97320630004024 Bioinformation 2009
Mutations found in the pncA gene of Mycobacterium tuberculosis in clinical pyrazinamide-resistant isolates from a local region of China. doi:10.1177/147323000903700517 names it J Int Med Res 2009
Characterisation of pncA mutations in clinical Mycobacterium tuberculosis isolates in New Zealand. doi:10.1080/00313020903071587 names it Pathology 2009
Genome analysis of multi- and extensively-drug-resistant tuberculosis from KwaZulu-Natal, South Africa. doi:10.1371/journal.pone.0007778 PLoS One 2009
Mycobacterium tuberculosis genotypic diversity in pyrazinamide-resistant isolates of Iran. doi:10.1089/mdr.2009.0066 Microb Drug Resist 2009
Comparison of phenotypic and genotypic methods for pyrazinamide susceptibility testing. Indian J Tuberc 2009
Characterization of pncA mutations of pyrazinamide-resistant Mycobacterium tuberculosis in Turkey. names it New Microbiol 2009
Sputum PCR-single-strand conformational polymorphism test for same-day detection of pyrazinamide resistance in tuberculosis patients. doi:10.1128/JCM.01594-08 J Clin Microbiol 2009
Effect of pyrazinamidase activity on pyrazinamide resistance in Mycobacterium tuberculosis. doi:10.1016/j.tube.2009.01.004 Tuberculosis (Edinb) 2009
In-depth molecular characterization of Mycobacterium tuberculosis from New Delhi--predominance of drug resistant isolates of the 'modern' (TbD1) type. doi:10.1371/journal.pone.0004540 PLoS One 2009
Molecular detection of drug-resistant Mycobacterium tuberculosis with a scanning-frame oligonucleotide microarray. doi:10.1007/978-1-59745-207-6_26 Methods Mol Biol 2009
[Determining drug resistance of the clinical strains of Mycobacterium tuberculosis to pyrazinamide]. Mol Gen Mikrobiol Virusol 2008
Pyrazinamide resistance among South African multidrug-resistant Mycobacterium tuberculosis isolates. doi:10.1128/JCM.00973-08 J Clin Microbiol 2008
Phenotypic and genotypic characterization of drug-resistant Mycobacterium tuberculosis strains. doi:10.1016/j.diagmicrobio.2008.06.013 Diagn Microbiol Infect Dis 2008
A single-step sequencing method for the identification of Mycobacterium tuberculosis complex species. doi:10.1371/journal.pntd.0000253 PLoS Negl Trop Dis 2008
Multidrug-resistant tuberculosis in Lisbon, Portugal: a molecular epidemiological perspective. doi:10.1089/mdr.2008.0798 Microb Drug Resist 2008
Pyrazinamide resistance and pncA gene mutations in Mycobacterium tuberculosis. doi:10.1128/AAC.00110-08 names it Antimicrob Agents Chemother 2008
Geography and genealogy of the human host harbouring a distinctive drug-resistant strain of tuberculosis. doi:10.1016/j.meegid.2007.11.008 Infect Genet Evol 2008
Characterization of Mycobacterium tuberculosis nicotinamidase/pyrazinamidase. doi:10.1111/j.1742-4658.2007.06241.x FEBS J 2008
Nitrate reductase assay for the rapid detection of pyrazinamide resistance in Mycobacterium tuberculosis using nicotinamide. doi:10.1093/jac/dkm418 J Antimicrob Chemother 2008
Evaluation of the BacT/ALERT PZA kit in comparison with the BACTEC 460TB PZA for testing Mycobacterium tuberculosis susceptibility to pyrazinamide. doi:10.1093/jac/dkm252 J Antimicrob Chemother 2007
Development and evaluation of a line probe assay for rapid identification of pncA mutations in pyrazinamide-resistant mycobacterium tuberculosis strains. doi:10.1128/JCM.00352-07 names it J Clin Microbiol 2007
Genetic and phenotypic characterization of drug-resistant Mycobacterium tuberculosis isolates in Hong Kong. doi:10.1093/jac/dkm054 J Antimicrob Chemother 2007
Discrepant results between pyrazinamide susceptibility testing by the reference BACTEC 460TB method and pncA DNA sequencing in patients infected with multidrug-resistant W-Beijing Mycobacterium tuberculosis strains. doi:10.1378/chest.06-1899 names it Chest 2007
Sequencing of the pncA gene in members of the Mycobacterium tuberculosis complex has important diagnostic applications: Identification of a species-specific pncA mutation in "Mycobacterium canettii" and the reliable and rapid predictor of pyrazinamide resistance. doi:10.1128/JCM.01454-06 names it J Clin Microbiol 2007
Detection of multidrug resistance in Mycobacterium tuberculosis. doi:10.1128/JCM.00750-06 J Clin Microbiol 2007
The paradox of pyrazinamide: an update on the molecular mechanisms of pyrazinamide resistance in Mycobacteria. J Commun Dis 2006
pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis clinical isolates from the southeast region of Brazil. doi:10.1093/jac/dkl363 names it J Antimicrob Chemother 2006
Frequency and implications of pyrazinamide resistance in managing previously treated tuberculosis patients. Int J Tuberc Lung Dis 2006
A new rapid and simple colorimetric method to detect pyrazinamide resistance in Mycobacterium tuberculosis using nicotinamide. doi:10.1093/jac/dkl231 J Antimicrob Chemother 2006
Detection of Mycobacterium avium & M. tuberculosis from human sputum cultures by PCR-RFLP analysis of hsp65 gene & pncA PCR. names it Indian J Med Res 2006
Temperature-mediated heteroduplex analysis for the detection of drug-resistant gene mutations in clinical isolates of Mycobacterium tuberculosis by denaturing HPLC, SURVEYOR nuclease. doi:10.1016/j.micinf.2005.06.008 Microbes Infect 2006
Spoligotyping and pncA polymorphism: a two step scenario for Mycobacterium bovis diagnosis in Portugal. doi:10.1016/s0873-2159(15)30528-6 names it Rev Port Pneumol 2005
Microarray-based pncA genotyping of pyrazinamide-resistant strains of Mycobacterium tuberculosis. doi:10.1099/jmm.0.46129-0 names it J Med Microbiol 2005
[Resistance to antituberculous drugs]. doi:10.1016/s0929-693x(05)80024-7 Arch Pediatr 2005
Detection by denaturing gradient gel electrophoresis of pncA mutations associated with pyrazinamide resistance in Mycobacterium tuberculosis isolates from the United States-Mexico border region. doi:10.1128/AAC.49.6.2210-2217.2005 names it Antimicrob Agents Chemother 2005
Analysis of rpoB and pncA mutations in the published literature: an insight into the role of oxidative stress in Mycobacterium tuberculosis evolution? doi:10.1093/jac/dki069 names it J Antimicrob Chemother 2005
Simple fibroblast-based assay to test the pyrazinamide susceptibility of Mycobacterium tuberculosis. doi:10.1128/AAC.49.2.804-807.2005 Antimicrob Agents Chemother 2005
Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis in Brazil. doi:10.1128/AAC.49.1.444-446.2005 names it Antimicrob Agents Chemother 2005
Characterization of drug-resistant isolates of Mycobacterium tuberculosis derived from Russian inmates. Int J Tuberc Lung Dis 2004
Molecular strain identification of the Mycobacterium tuberculosis complex in archival tissue samples. doi:10.1136/jcp.2003.015719 J Clin Pathol 2004
Silent nucleotide polymorphisms and a phylogeny for Mycobacterium tuberculosis. doi:10.3201/eid1009.040046 Emerg Infect Dis 2004
[Molecular identification of mycobacteria and detection of antibiotic resistance]. Ann Biol Clin (Paris) 2004
Calmette-Guérin bacillus sternal osteomyelitis diagnosed by DNA sequencing analysis of PNC A. doi:10.1097/01.inf.0000134311.89819.fd Pediatr Infect Dis J 2004
Spectrum of pncA mutations in multidrug-resistant Mycobacterium tuberculosis isolates obtained in Latvia. doi:10.1128/AAC.48.8.3209-3210.2004 names it Antimicrob Agents Chemother 2004
pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates in Portugal. doi:10.1128/AAC.48.7.2736-2738.2004 names it Antimicrob Agents Chemother 2004
Genetic polymorphism in Mycobacterium tuberculosis isolates from patients with chronic multidrug-resistant tuberculosis. doi:10.1086/421501 J Infect Dis 2004
Genomic characterization of an endemic Mycobacterium tuberculosis strain: evolutionary and epidemiologic implications. doi:10.1128/JCM.42.6.2573-2580.2004 J Clin Microbiol 2004
Accurate mapping of mutations of pyrazinamide-resistant Mycobacterium tuberculosis strains with a scanning-frame oligonucleotide microarray. doi:10.1016/j.diagmicrobio.2004.01.001 Diagn Microbiol Infect Dis 2004
A pncA polymorphism to differentiate between Mycobacterium bovis and Mycobacterium tuberculosis. doi:10.1016/j.mcp.2003.11.006 names it Mol Cell Probes 2004
BCG lymphadenopathy detected in a BCG-vaccinated infant. doi:10.1590/s0100-879x2004000500011 Braz J Med Biol Res 2004
The 500-base-pair fragment of the putative gene RvD1-Rv2031c is also present in the genome of Mycobacterium tuberculosis. In Vivo 2004
Temperature-mediated heteroduplex analysis for detection of pncA mutations associated with pyrazinamide resistance and differentiation between Mycobacterium tuberculosis and Mycobacterium bovis by denaturing high- performance liquid chromatography. doi:10.1128/JCM.42.3.1016-1023.2004 names it J Clin Microbiol 2004
Genetic and phenotypic characterization of pyrazinamide-resistant mycobacterium tuberculosis complex isolates in Japan. doi:10.1016/j.diagmicrobio.2003.09.013 Diagn Microbiol Infect Dis 2004
Elevation of Mycobacterium tuberculosis subsp. caprae Aranaz et al. 1999 to species rank as Mycobacterium caprae comb. nov., sp. nov. doi:10.1099/ijs.0.02532-0 Int J Syst Evol Microbiol 2003
[Tuberculous epididymitis caused by intravesical BCG therapy: a case report]. Hinyokika Kiyo 2003
Correlation between pyrazinamide activity and pncA mutations in Mycobacterium tuberculosis isolates in Taiwan. doi:10.1128/AAC.47.11.3672-3673.2003 names it Antimicrob Agents Chemother 2003
Widespread pyrazinamide-resistant Mycobacterium tuberculosis family in a low-incidence setting. doi:10.1128/JCM.41.7.2878-2883.2003 J Clin Microbiol 2003
An assessment of a multiplex PCR assay for differentiating clinically important mycobacteria based on pncA gene variation. doi:10.1016/s0890-8508(03)00004-5 names it Mol Cell Probes 2003
The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis 2003
Evaluation of BACTEC MGIT 960 PZA medium for susceptibility testing of Mycobacterium tuberculosis to pyrazinamide (PZA): compared with the results of pyrazinamidase assay and Kyokuto PZA test. doi:10.1016/s0732-8893(02)00471-6 Diagn Microbiol Infect Dis 2002
[Clinical application and evaluation of the detection of five drugs resistance genes in Mycobacterium tuberculosis]. Zhonghua Jie He He Hu Xi Za Zhi 2002
Identification of the causative organism of tuberculous lymphadenitis in ethiopia by PCR. doi:10.1128/JCM.40.11.4230-4234.2002 J Clin Microbiol 2002
Selection of in vitro mutants of pyrazinamide-resistant Mycobacterium tuberculosis. doi:10.1016/s0924-8579(02)00182-6 Int J Antimicrob Agents 2002
A multiplex-PCR for the differentiation of Mycobacterium bovis and Mycobacterium tuberculosis. doi:10.1111/j.1574-6968.2002.tb11322.x FEMS Microbiol Lett 2002
Characterization of pyrazinamide and ofloxacin resistance among drug resistant Mycobacterium tuberculosis isolates from Singapore. doi:10.1016/s1201-9712(02)90136-0 Int J Infect Dis 2002
Pyrazinamide resistance associated with pncA gene mutation in Mycobacterium tuberculosis in Japan. doi:10.1017/s0950268801006744 names it Epidemiol Infect 2002
Temperature-mediated heteroduplex analysis performed by using denaturing high-performance liquid chromatography to identify sequence polymorphisms in Mycobacterium tuberculosis complex organisms. doi:10.1128/JCM.40.5.1610-1616.2002 J Clin Microbiol 2002
Biochemical and genetic evidence for the transfer of Mycobacterium tuberculosis subsp. caprae Aranaz et al. 1999 to the species Mycobacterium bovis Karlson and Lessel 1970 (approved lists 1980) as Mycobacterium bovis subsp. caprae comb. nov. doi:10.1099/00207713-52-2-433 Int J Syst Evol Microbiol 2002
Rapid detection of pyrazinamide-resistant Mycobacterium tuberculosis by a PCR-based in vitro system. doi:10.1128/JCM.40.2.501-507.2002 J Clin Microbiol 2002
New mutations in pncA of in vitro selected pyrazinamide-resistant strains of Mycobacterium tuberculosis. doi:10.1089/10766290152652765 names it Microb Drug Resist 2001
Genetic diversity among Mycobacterium bovis isolates: a preliminary study of strains from animal and human sources. doi:10.1128/JCM.39.12.4558-4562.2001 J Clin Microbiol 2001
Characterization of pncA mutations of pyrazinamide-resistant Mycobacterium tuberculosis in Korea. doi:10.3346/jkms.2001.16.5.537 names it J Korean Med Sci 2001
Characterisation of the pncA gene in Mycobacterium tuberculosis isolates from Gauteng, South Africa. names it Int J Tuberc Lung Dis 2001
pncA mutations in clinical Mycobacterium tuberculosis isolates from Korea. doi:10.1186/1471-2334-1-4 names it BMC Infect Dis 2001
Study of the structure-activity relationships for the pyrazinamidase (PncA) from Mycobacterium tuberculosis. doi:10.1042/0264-6021:3530453 names it Biochem J 2001
Pyrazinamide-monoresistant Mycobacterium tuberculosis in the United States. doi:10.1128/JCM.39.2.647-650.2001 J Clin Microbiol 2001
Genetic diversity of Mycobacterium africanum clinical isolates based on IS6110-restriction fragment length polymorphism analysis, spoligotyping, and variable number of tandem DNA repeats. doi:10.1128/JCM.39.1.57-65.2001 J Clin Microbiol 2001
[Studies on pncA gene mutations in M. tuberculosis isolates]. names it Zhonghua Jie He He Hu Xi Za Zhi 2000
Correlation of pncA sequence with pyrazinamide resistance level in BACTEC for 21 mycobacterium tuberculosis clinical isolates. doi:10.1089/mdr.2000.6.283 names it Microb Drug Resist 2000
Genetic diversity and evidence for acquired antimicrobial resistance in Mycobacterium tuberculosis at a large hospital in South India. doi:10.1016/s1201-9712(00)90075-4 Int J Infect Dis 2000
[Molecular mechanisms of multidrug resistance in Mycobacterium tuberculosis]. doi:10.7888/juoeh.22.269 J UOEH 2000
Comparison of phenotypic and genotypic methods for pyrazinamide susceptibility testing with Mycobacterium tuberculosis. doi:10.1128/JCM.38.10.3686-3688.2000 J Clin Microbiol 2000
Genotypic determination of Mycobacterium tuberculosis antibiotic resistance using a novel mutation detection method, the branch migration inhibition M. tuberculosis antibiotic resistance test. doi:10.1128/JCM.38.10.3656-3662.2000 J Clin Microbiol 2000
Expression of Mycobacterium smegmatis pyrazinamidase in Mycobacterium tuberculosis confers hypersensitivity to pyrazinamide and related amides. doi:10.1128/JB.182.19.5479-5485.2000 J Bacteriol 2000
Phenotypic characterization of pncA mutants of Mycobacterium tuberculosis. doi:10.1128/AAC.44.9.2291-2295.2000 names it Antimicrob Agents Chemother 2000
Simultaneous identification and typing of multi-drug-resistant Mycobacterium tuberculosis isolates by analysis of pncA and rpoB. doi:10.1099/0022-1317-49-7-651 names it J Med Microbiol 2000
Mycobacterium smegmatis has two pyrazinamidase enzymes, PncA and pzaA. doi:10.1128/JB.182.13.3881-3884.2000 names it J Bacteriol 2000
Molecular characterization of pncA gene mutations in Mycobacterium tuberculosis clinical isolates from China. doi:10.1017/s0950268899003635 names it Epidemiol Infect 2000
pncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: spread of a monoresistant strain in Quebec, Canada. doi:10.1128/AAC.44.3.528-532.2000 names it Antimicrob Agents Chemother 2000
Molecular characterization of mycobacteria isolated from seals. doi:10.1099/00221287-145-9-2519 Microbiology (Reading) 1999
Relationship between pyrazinamide resistance, loss of pyrazinamidase activity, and mutations in the pncA locus in multidrug-resistant clinical isolates of Mycobacterium tuberculosis. doi:10.1128/AAC.43.9.2317 names it Antimicrob Agents Chemother 1999
Mycobacterium tuberculosis subsp. caprae subsp. nov.: a taxonomic study of a new member of the Mycobacterium tuberculosis complex isolated from goats in Spain. doi:10.1099/00207713-49-3-1263 Int J Syst Bacteriol 1999
pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates from northwestern Russia. doi:10.1128/AAC.43.7.1764 names it Antimicrob Agents Chemother 1999
Characterization of new mutations in pyrazinamide-resistant strains of Mycobacterium tuberculosis and identification of conserved regions important for the catalytic activity of the pyrazinamidase PncA. doi:10.1128/AAC.43.7.1761 names it Antimicrob Agents Chemother 1999
[pncA gene mutations in clinical isolates of tubercle bacillus by polymerase chain reaction-direct sequencing method: in relationship to pyrazinamide resistance]. names it Kekkaku 1999
Molecular markers demonstrate that the first described multidrug-resistant Mycobacterium bovis outbreak was due to Mycobacterium tuberculosis. doi:10.1128/JCM.37.4.971-975.1999 J Clin Microbiol 1999
Reduced pyrazinamidase activity and the natural resistance of Mycobacterium kansasii to the antituberculosis drug pyrazinamide. doi:10.1128/AAC.43.3.537 Antimicrob Agents Chemother 1999
Genotypic characterization of drug-resistant Mycobacterium tuberculosis isolates from Peru. doi:10.1054/tuld.1998.0013 Tuber Lung Dis 1998
Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. doi:10.1054/tuld.1998.0002 Tuber Lung Dis 1998
Novel pncA Mutations in Pyrazinamide-Resistant Isolates of Mycobacterium tuberculosis. doi:10.154/MODI00300229 names it Mol Diagn 1998
[Mechanisms of drug-resistance in mycobacteria]. Nihon Rinsho 1998
[Multidrug-resistant tuberculosis. 2. Mechanisms of drug-resistance in Mycobacterium tuberculosis--genetic mechanisms of drug-resistance]. Kekkaku 1998
Purification, gene cloning, targeted knockout, overexpression, and biochemical characterization of the major pyrazinamidase from Mycobacterium smegmatis. doi:10.1128/JB.180.22.5809-5814.1998 J Bacteriol 1998
Differentiation of BCG-induced lymphadenitis from tuberculosis in lymph node biopsy specimens by molecular analyses of pncA and oxyR. doi:10.1002/(SICI)1096-9896(199801)184:1<96::AID-PATH989>3.0.CO;2-M names it J Pathol 1998
Allele-specific PCR method based on pncA and oxyR sequences for distinguishing Mycobacterium bovis from Mycobacterium tuberculosis: intraspecific M. bovis pncA sequence polymorphism. doi:10.1128/JCM.36.1.239-242.1998 names it J Clin Microbiol 1998
Absence of the genetic marker IS6110 from a strain of Mycobacterium tuberculosis isolated in Ontario. doi:10.1155/1998/292491 Can J Infect Dis 1998
Molecular techniques in the diagnosis of drug-resistant tuberculosis. Ann Acad Med Singap 1997
[Rapid diagnosis of tuberculosis]. Kekkaku 1997
The pncA gene from naturally pyrazinamide-resistant Mycobacterium avium encodes pyrazinamidase and confers pyrazinamide susceptibility to resistant M. tuberculosis complex organisms. doi:10.1099/00221287-143-10-3367 names it Microbiology (Reading) 1997
Mutations associated with pyrazinamide resistance in pncA of Mycobacterium tuberculosis complex organisms. doi:10.1128/AAC.41.3.636 names it Antimicrob Agents Chemother 1997
Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. doi:10.1128/AAC.41.3.540 names it Antimicrob Agents Chemother 1997
Mutation in pncA is a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis. doi:10.1016/s0962-8479(98)80004-x names it Tuber Lung Dis 1997
Rapid differentiation of bovine and human tubercle bacilli based on a characteristic mutation in the bovine pyrazinamidase gene. doi:10.1128/jcm.35.1.106-110.1997 J Clin Microbiol 1997
Identification, cloning, and expression of the Escherichia coli pyrazinamidase and nicotinamidase gene, pncA. doi:10.1128/AAC.40.6.1426 names it Antimicrob Agents Chemother 1996
Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. doi:10.1038/nm0696-662 names it Nat Med 1996

Title+abstract index only: a paper that names this gene solely in its body text, a figure legend or a supplement is invisible here. That is why this list sits beside the curated layer rather than replacing it - Rv0007's characterisation, found by a full-text sweep, returns zero in this one. Absence from this list is not absence from the literature. Source: PubMed E-utilities sweep (esearch + esummary), every alias of the gene searched in conjunction with a mycobacterial context term; ambiguous common-word aliases excluded. phase198, 2026-09-06.

This layer CITES the literature and adds context; it does not change the verdict or the function stated elsewhere in this fiche. This distinguishes a gene that is dark because nobody has looked from one that is dark despite having been studied. Source: PubMed (whole): H37Rv locus tag + GENE NAME + ortholog identifiers (Mb…, MMAR_…, MSMEG_…, ML…, MAB_…), under a mycobacterial context filter; hits verified against the abstract text. Species-context counts distinguish M. tuberculosis literature from literature on other mycobacteria. phase76/phase77, 2026-07-13.

Genomic-neighbour overlap (structural caveat) co-directional · 0 % of gene

NeighbourRv2042c (Rv2042c, - strand)
Overlap1 bp, 0 % of this gene's length

co-directional overlap: ordinary (e.g. shared stop/start codons in an operon), not the Rv2438A-type artefact P20.1, derived from GFF3 gene coordinates, 2026-08-03.

CRISPRi vulnerability

Vulnerability index 1.11 (95% CI -0.94 to 4.62). A more negative index = more vulnerable to knockdown (better drug-target quality); indicative threshold VI ≤ -6 = highly vulnerable.

Quantitative CRISPRi knockdown, graded (finer than binary Tn-seq essentiality). Source: CRISPRi vulnerability index (Bosch 2021, supplementary Table S2 'mmc3.xlsx', bulk import via Europe PMC -- supersedes the per-gene pebble.rockefeller.edu scrape of phase46_crispri_vulnerability.py).

Caveat on this estimate. Bosch et al. flag this gene's vulnerability estimate as NOT certain, and here that call has a mechanical cause visible in the library itself: every guide targeting this gene is >=21 nt (str_span=0.087 on a 0-1 scale, near the genome floor), and guide repression strength saturates from 21 nt on -- so the library never sampled a partial knockdown for this gene, only the near-maximal repression plateau. The dose-response fit (and this VI) is therefore essentially unconstrained by data, not merely uncertain -- a limitation of the CRISPRi library design for the non-essential class (Bosch et al. 2021), not a defect in this specific measurement. n_guides=7 is descriptive only and does not predict this. Do not cite this VI as a standalone vulnerability claim.

Legacy record & comparison (Mycobrowser)

Mycobrowser functionConverts amides such as nicotinamide to corresponding acid.
Mycobrowser EC 3.5.1.- · agrees with the atlas

The legacy Mycobrowser record is shown for verification. Mycobrowser is no longer maintained; its EC numbers predate recent nomenclature revisions, so a class change usually reflects re-numbering, not a conflict.

Orthologues (reciprocal best hits across mycobacteria)

M. bovis Mb2069c · 99.5% identity
M. marinum MMAR_3016 · 69.2% identity
M. smegmatis MSMEG_6506 · 66.5% identity
M. orygis RJtmp_002115 · 100.0% identity
M. abscessus MAB_1472c · 59.3% identity

Reciprocal-best-hit orthologues (DIAMOND) against the Mycobrowser reference proteomes. A missing species is informative: e.g. a gene absent from M. leprae was likely lost in its reductive genome evolution. Locus tags link to Mycobrowser.

Curated reference (UniProt)

UniProt I6XD65 SwissProt · reviewed · Evidence at protein level
UniProt nameNicotinamidase/pyrazinamidase
EC (curated) EC 3.5.1.-, EC 3.5.1.19
Curated functionCatalyzes the deamidation of nicotinamide (NAM) into nicotinate. Likely functions in the cyclical salvage pathway for production of NAD from nicotinamide (By similarity)..; FUNCTION: Is involved in the activation of the first-line antituberculous drug pyrazinamide (PZA) by converting it into the active form, pyrazinoic acid.

Functional vocabulary (eggNOG-mapper, orthology transfer)

COG category Q Secondary metabolites biosynthesis, transport and catabolism
Preferred namepncA
eggNOG descriptionIsochorismatase family
Orthologous groupCOG1335
EC number EC 3.5.1.19
KEGG orthology K08281
KEGG pathways map00760, map01100
Gene Ontology (39) GO:0003674, GO:0003824, GO:0005488, GO:0005506, GO:0005575, GO:0005622, GO:0005623, GO:0005737, GO:0006766, GO:0006767, GO:0006769, GO:0006807 +27 more

Orthology-based transfer (eggNOG 5.0.2, diamond). EC/KO/GO/CAZy are computed annotations, not manual curation; cross-check against the primary literature before treating a specific reaction as established.

Conservation & selection (intra-MTBC, 142 601 strains, snapshot of 2026-09-29)

pN/pS 11.271 · diversifying/relaxed
Polymorphic sites (≥ 0.1% of strains) 1 synonymous, 33 missense, 1 nonsense, 2 frameshift
Disruption 3 distinct premature-stop/frameshift site(s); most common in 0.40% of strains (571) · clonal
Which clade carries which site (attribution) aucun site fixé dans un clade; union over all sites: 1 077 strains (the count above is a maximum over sites, not a union).
  • NC_000962.3:2288723:T:TC · frameshift · 571 strains — not fixed in any clade
  • NC_000962.3:2288932:G:C · nonsense · 266 strains — not fixed in any clade
  • NC_000962.3:2288849:A:ACC · frameshift · 240 strains — not fixed in any clade
Which clade carries which disrupting site — the question the count above never asked. `disrupt_strains` is a MAXIMUM over sites, not a union: two sites carried by two disjoint clades do not add up there. `disrupt_mode` is derived from the NUMBER of sites alone (convergent at 4 or more), so it says nothing about who carries them. Read this field instead for any evolutionary claim, and mind the distinction it enforces: several clades at the SAME site is shared ancestry, not convergence — convergence requires DIFFERENT sites in DIFFERENT clades. SECOND CORRECTION (P44.8, same day): a clade name listed here is the ROOT of the fine clade that fixes the site, not the whole lineage. Across the 789 fixed sites of this atlas, the fixing sub-clades cover a median of 9.2% of the lineage named, and under 10% for half of them — so read the sub-clade sizes given here, never the lineage name alone.

Read the disruption percentage against its ceiling, not against 100%. The strain collection is deeply imbalanced by clade, so a loss fixed in an entire lineage still shows a small overall fraction: a gene disrupted in every L6 strain caps at 0.96% of the collection, in every M. caprae strain at 0.20%, in every M. microti strain at 0.02%. Of the 705 clades in this collection, 689 have a ceiling below 1%. A figure of "0.15% of strains" is therefore uninterpretable on its own — it can be noise or a complete, lineage-defining loss. Use the clade attribution row above, which gives the sub-clade sizes, and never read the percentage alone.

pN/pS from segregating SNPs (singletons removed) normalised by possible sites. Low pN/pS = purifying selection (a strong signal that a "hypothetical" is a real, constrained gene). A high pN/pS is ambiguous: relaxed constraint or positive selection (drug resistance, antigenic variation) inflate it; e.g. rpoB/katG/pncA score high here for resistance, not loss of function. A clonal disruption (one allele over a clade) suggests lineage pseudogenisation; a convergent one (many independent alleles) is typical of resistance loss-of-function.

Outgroup conservation (beyond the MTBC) Bacteria

M. canettii dN/dS (deep-divergence selection) 0.0 (low power) · 1 consensus substitution(s)
low power (1 canettii-consensus substitution(s)); present in M. canettii but dN/dS not reliable
Limitation: dN/dS mixes fixed canettii-H37Rv divergence with intra-canettii polymorphism, and is not polarised (the per-gene repolarisation is not viable: 79 % of the consensus SPDI lie outside the polarised table).
Genus-wide presence (~53 non-MTBC Mycobacterium) present in 52/53 (98%) · mean identity 71.8% · 4/4 closest MTBAP relatives
conserved across the genus (present in 52/53 non-MTBC Mycobacterium genomes, incl. distant relatives) — an ancient core gene predating the genus radiation
Phylostratum (deepest detected homolog) MTBC-specific → Mycobacterium → Mycobacteriaceae → Corynebacteriales → Actinomycetia → Bacteria
detected in 11/13 non-Mycobacterium reference genomes (down to Bacteria) · mean identity 54.4%
detected down to outside the phylum (Proteobacteria/Firmicutes controls) — a universally conserved, ancient bacterial gene

Two orthogonal outgroup signals. M. canettii (the immediate outgroup) gives a deep-divergence dN/dS (a low value confirms a constrained, real gene; shown as confident only at ≥8 substitutions, else flagged low-power). Genus-wide presence/absence (tblastn vs assembled non-MTBC genomes) places the gene on the ancient-core ↔ MTBC-specific axis: a gene absent even from the closest MTBAP relatives is a candidate MTBC-specific innovation (possible host-adaptation factor, to confirm by synteny). The phylostratum extends that axis outside the genus (tblastn vs 13 reference genomes spanning Mycobacteriaceae → Corynebacteriales → Actinomycetia → outside the phylum): it is the deepest clade in which a homolog is still detected, i.e. a proxy for gene age. Read it with the null model in mind: a shallow (young) stratum can also reflect homology-detection failure for short or fast-evolving ORFs, so it is a descriptive axis, not a proof of novelty.

Essentiality (transposon mutagenesis)

DeJesus 2017 callNE · non-essential
What the call meansnon-essential
TA sites (Himar1) 12 in the ORF — 0 in the essential state, 0 growth-defect, 12 non-essential, 0 growth-advantage. Saturation 0.917, mean read count 83.6363636364. A region of the protein devoid of TA sites is invisible to this assay: nothing can be inferred about it, in either direction.
All 12 sites lie in this ORF alone (no overlapping CDS shares any), so the call is attributable to this gene.

Genome-wide Himar1 transposon essentiality in H37Rv (DeJesus 2017). An essential call (ES/ESD/GD) is strong, independent evidence that a "hypothetical" locus encodes a functional, selectively required gene — orthogonal to intra-species conservation.

Conditional fitness (RB-TnSeq, 95 conditions) stress

ConditionGroupDirectionlog2 fitnesst
Pyrazinamide stress mutant enriched (loss advantageous) 2.446 7.862

Randomly-barcoded transposon screen across 95 carbon/nitrogen sources, pH, stressors and antibiotics (1 condition-specific phenotype(s) for this gene). A conditional fitness phenotype is a context lead, not a proven function, and never changes the verdict here. Note the blind spot: RB-TnSeq cannot measure essential genes. Source: RB-TnSeq 95-condition barcoded transposon screen, Mtb (PLoS Biol 2026, doi:10.1371/journal.pbio.3003529).

Mutant phenotypes (conditional Tn-seq, MtbTnDB) in-vivo phenotype

Conditionlog2FCqEffect
fitness in mouse infection (in vivo) +2.600.0 disruption advantageous
fitness in mouse infection (in vivo) +2.550.0 disruption advantageous
altered fitness under high iron concentrations (stress) -2.550.05 required
fitness in mouse infection (in vivo) +2.490.0 disruption advantageous
fitness in mouse infection (in vivo) +2.440.0 disruption advantageous
fitness in mouse infection (in vivo) +2.420.0 disruption advantageous
fitness in mouse infection (in vivo) +2.220.0 disruption advantageous
fitness in mouse infection (in vivo) +2.020.0 disruption advantageous
fitness in mouse infection (in vivo) +1.440.025 disruption advantageous

Conditional fitness of transposon-disruption mutants across 9 significant condition(s) (|log2FC|≥1, q≤0.05), from the standardized MtbTnDB compendium. A negative log2FC means the mutant is depleted — the gene contributes to fitness in that condition. An in-vivo defect for a "hypothetical" is strong evidence it matters for infection, even without a known molecular function. Disruption (Tn insertion), not a clean deletion; genetic-interaction screens excluded.

Drug resistance (WHO catalogue) pyrazinamide

pyrazinamide1193 catalogued resistance-associated variant(s)

This gene carries mutations classed Associated with resistance (WHO grade 1–2) in the consolidated catalogue (WHO 2nd ed. 2023 + tb-profiler). Only the R-associated tier is shown; "uncertain" and empirical-only signals are excluded. Test a specific strain or variant with the resistance tester. Research context, not a clinical diagnostic.

Proteomics (mass spectrometry) detected

MS detectiondetected in 12 of 16 independent MS datasets
Integrated abundance96.4 ppm · rank 1317/3519 (62.6th percentile)

Detection by mass spectrometry is direct, experimental evidence that the protein product exists — orthogonal to sequence conservation and to Tn-seq essentiality, and especially decisive for a "hypothetical" locus. Read the dataset count as abundance, not as replication. Measured across this atlas (3,491 detected proteins), the number of datasets a protein appears in tracks its abundance almost monotonically: median 1.2 ppm at 1 dataset of 16, 27 ppm at 10, 392 ppm at 15, 1,325 ppm at 16 — three orders of magnitude. A high count therefore says the protein is abundant more than it says several independent experiments confirmed it. What the count does establish, at any value, is that the product exists.

Predicted localisation (DeepTMHMM + lipobox) no export signal, no TM helix

Predictionno signal peptide, no TM helix (DeepTMHMM class GLOB)
DeepTMHMM classGLOB

A verified absence of signals, which is not a compartment. No Sec/Tat signal peptide, no transmembrane helix and no lipobox were found on this sequence. The predictor reports topology and export signals; it does not measure where the protein ends up, so this page draws no cytoplasmic conclusion from it. In M. tuberculosis that reservation is not theoretical: the 12 Esx paralogues of this atlas — EsxA/ESAT-6 and EsxB/CFP-10 among them, the best-established secreted proteins of the species — carry this very call, because substrates of the type VII (ESX) secretion system leave no recognisable signal. « Secreted » and « no signal peptide » are true together here.

Transmembrane topology and signal peptide from DeepTMHMM (deep-learning reference predictor); lipoproteins from a (myco)bacterial lipobox motif. A sequence-based prediction of subcellular context.

Physico-chemical properties (computed, ProtParam)

Length186 aa
Molecular weight19.6 kDa
Theoretical pI4.43
GRAVY0.002 (hydrophobic)
Aliphatic index83.9
Aromaticity0.075
Instability index10.4 (stable)

Computed from the ancestral MTBC0 sequence with the ExPASy ProtParam method (Biopython). Descriptive biophysical context: a positive GRAVY flags a hydrophobic (often membrane) protein, a high instability index (>40) predicts a short in-vitro half-life, an extreme pI hints at compartment or binding partner.

Domains (Pfam, hmmscan --cut_ga)

PfamAccessioni-EvalueResiduesDescription
IsochorismatasePF00857.27 1.1e-293–182 Isochorismatase domain

3D structure (interactive — Mol*/pdbe-molstar)

Experimental structure 3pl1 (PDBe), the strongest available structural evidence for this gene. Drag to rotate, scroll to zoom; hetero-groups (ligands, ions, waters hidden by default) shown as sticks.

Experimental structures (Protein Data Bank) 1 solved

PDBMethodResolutionCoverage
3pl1 X-ray diffraction 2.2 Å 100%

Experimentally solved structures mapped from the UniProt accession via PDBe/SIFTS (1 total; up to 8 shown, ranked by sequence coverage then resolution). An experimental structure is direct proof of the folded product and the strongest structural evidence — superseding the predicted ESMFold/AlphaFold models below for any covered region.

Structural search (AlphaFold DB model, Foldseek vs PDB — genome-wide) pLDDT 97.3

PDB hitprobTM (aln)TM (query)TM (target)Seq. id.Cov. q / tE-valueDescription
3pl1-assembly1_A 1.00 0.99 0.98 0.99 100% 99% / 100% 5.7e-36 sig 3pl1-assembly1_A Determination of the crystal structure of the pyrazinamidase from M.tuberculosis : a structure-function analysis for prediction resistance to pyrazinamide.
3r2j-assembly2_C 1.00 0.87 0.87 0.82 40% 100% / 93% 5.3e-18 sig 3r2j-assembly2_C Crystal Structure of PnC1 from L. infantum in complex with nicotinate
1im5-assembly1_A 1.00 0.85 0.82 0.85 36% 98% / 98% 1.7e-16 sig 1im5-assembly1_A Crystal Structure of Pyrazinamidase of Pyrococcus horikoshii in Complex with Zinc
2wt9-assembly1_A 1.00 0.80 0.80 0.72 34% 99% / 96% 6.4e-17 sig 2wt9-assembly1_A Acinetobacter baumanii nicotinamidase pyrazinamidease
3hb7-assembly4_G 1.00 0.78 0.76 0.78 26% 99% / 94% 3.4e-12 sig 3hb7-assembly4_G The Crystal Structure of an Isochorismatase-like Hydrolase from Alkaliphilus metalliredigens to 2.3A

Foldseek search of the AlphaFold DB model (mean pLDDT 97.3, gated at 70) against the PDB — a genome-wide extension of the ESMFold dark-gene search that also covers proteins beyond the single-sequence length limit. Confident structural neighbours (E < 0.01) shown.

Catalytic-site verification (M-CSA on the structural model)

M-CSA entry716 · EC 3.5.1.19
Catalytic residues7/9 identical (9/9 aligned)
VerdictPARTIAL (7/9 identical, 9/9 aligned) -> active site partly retained; verify (possible distant homolog / weak alignment)

Catalytic residues of the matched M-CSA reference enzyme mapped onto the structural model by alignment. An active-site-conserved verdict upgrades a mere fold match to a likely active enzyme; fold-only flags a shared fold whose catalytic machinery is not retained (a guard against over-calling).

Genomic context (neighbours & predicted operon) operon of 8

Upstream (5' on genome)Rv2042c (- strand, -1 bp gap)
Downstream (3' on genome)Rv2044c (- strand, 40 bp gap)
Predicted operon Rv2037c · Rv2038c · Rv2039c · Rv2040c · Rv2041c · Rv2042c · pncA · Rv2044c

Neighbours from the H37Rv annotation (- strand). The operon is predicted by co-directional intergenic distance (same strand, gaps ≤50 bp) — a transcription-unit hypothesis, not a mapped TSS. For a "hypothetical", co-transcription with a characterised operon is a concrete functional lead (complements the STRING neighborhood channel below).

Published operon evidence (two independent sources)

Roback 2007 (logistic regression: distance + expression correlation, 474 microarrays) no multi-gene operon predicted (singleton) — disagrees with the distance heuristic above
REMap 2016 (RNA-seq coverage continuity, CDC1551, tag MT2103) exponential phase: operon of 2, Rv2042c · Rv2043c (coverage 53.58)
stationary phase: operon of 2, Rv2042c · Rv2043c (coverage 35.95) — disagrees with the distance heuristic above

Two independent published operon maps, cited alongside the distance heuristic above: an association corroborating or contradicting the heuristic, never proof of shared function. REMap's RNA-seq coverage continuity is the most direct of the three signals; Roback's logistic regression and the intergenic-distance heuristic are statistical proxies.

Functional interaction network (STRING v12, guilt-by-association)

Explore full network →

Node colour = verdict, dashed = still uncharacterised; edge colour = evidence (green experimental, orange genomic-context, grey co-expression), width ∝ score. Click a partner to open its page; "Explore full network" to walk the graph.

Closest characterised functional partner: pncB1 (nicotinic acid phosphoribosyltransferase PncB1), high confidence (score 988, all STRING channels except text-mining; the partner is chosen on its genomic-context evidence). The pair is recorded in a curated database (pathway or complex membership) for M. tuberculosis genes themselves (score ≥ 200): a curated association, not a measurement in this organism.

Showing the 15 strongest of this gene's 101 partners at medium confidence (28 at high confidence). The table is an extract, not a neighbourhood: across the proteome the real median degree is 34 while the served median is 15, so no hub, degree distribution or centrality may be read on this table. None of the 101 partners rests on an interaction measured in M. tuberculosis itself.

PartnerProductScoreNo text-miningChannels (≥400)
Rv1330c pncB1 curated nicotinic acid phosphoribosyltransferase PncB1 994 988 ctx fusion:567 cooccurence:654 database:900 textmining:585
Rv0573c pncB2 curated nicotinic acid phosphoribosyltransferase PncB2 987 977 ctx fusion:410 cooccurence:572 database:900 textmining:475
Rv1151c cobB curated NAD-dependent protein deacylase 927 917 database:900
Rv3393 iunH curated nucleoside hydrolase 928 913 database:900
Rv3307 deoD curated purine nucleoside phosphorylase 908 903 database:900
Rv2042c hypothetical protein 943 888 ctx neighborhood:882 textmining:514
Rv2041c sugar ABC transporter substrate-binding lipoprotein 693 694 ctx neighborhood:684
Rv2044c hypothetical protein 888 691 ctx neighborhood:690 textmining:652
Rv2037c transmembrane protein 674 675 ctx neighborhood:664
Rv2040c sugar ABC transporter permease 670 671 ctx neighborhood:666
Rv2039c sugar ABC transporter permease 669 670 ctx neighborhood:666
Rv2038c ugpC sugar ABC transporter ATP-binding protein 668 669 ctx neighborhood:666
Rv3433c nnr bifunctional ADP-dependent (S)-NAD(P)H-hydrate dehydratase/NAD(P)H-hydrate epimerase 653 654 coexpression:644
Rv2045c lipT carboxylesterase LipT 576 575 ctx neighborhood:569
Rv2982c gpdA2 glycerol-3-phosphate dehydrogenase 522 505 coexpression:412

STRING combines evidence channels (neighborhood, fusion, cooccurrence, coexpression, experimental, database, text-mining) into a 0–1000 score. The ctx badge marks edges carried by the genomic-context channels (conserved neighborhood, fusion, phylogenetic co-occurrence), which are independent of orthology and structure and the strongest signal for an unknown gene. The no text-mining column recomputes the score from data alone, so a link that does not depend on the literature is visible. Association is a function hypothesis, not proof: corroborate with the operon context and the primary literature before assigning a function.

Where the experimental evidence comes from, and why it matters here. STRING's experimental channel fuses interactions measured in M. tuberculosis with interactions measured in another organism and transferred to this pair by orthology. The two are not equivalent for this atlas, whose standing rule is that better studied elsewhere is not a function established in M. tuberculosis. Measured on the served network: of the 38 229 partner pairs shown across the atlas, 13 483 partner rows carry a non-zero experimental channel, and only 106 pairs rest on an interaction measured in M. tuberculosis itself — 0.3 % of the network. Those 106 are long-established complexes (ESX-1/ESAT-6, RNA polymerase with CarD and RbpA, the Pup–Mpa proteasome, gyrase, Emb, GarA with PknB and PknG, the Rel modules); no still-uncharacterised gene is among them. The reason is not a gap in this atlas but in the literature: there is almost no experimental interactome of this bacterium, IntAct holding 134 curated protein pairs for a ~4 000-gene proteome. A exp (transferred) badge is therefore a lead, never a measurement, and an absence of badge is not evidence that the pair does not interact.

Evidence

  • Legacy H37Rv annotation: pyrazinamidase/nicotinamidase PncA
  • MTBC0 PGAP product: pyrazinamidase PncA
  • Pfam (hmmscan --cut_ga): Isochorismatase PF00857.27 (E=1e-29)
  • (auto-curated by rules from PGAP + Pfam + Foldseek; not hand-reviewed)

Sources

  • Ancestral sequence & coordinates: Harrison LB et al. (2024), An imputed ancestral reference genome for the MTBC, doi:10.1101/2023.09.07.556366
  • Product annotation: NCBI PGAP on MTBC0; legacy from H37Rv NC_000962.3 (RefSeq NP_216559.1)
  • Domains: Pfam-A via hmmscan --cut_ga — Isochorismatase (PF00857.27)
  • Sequence-level signal: ESM Atlas (EvolutionaryScale × BioHub) — exploratory
  • Controlled vocabulary: eggNOG-mapper 2.1.12 (Cantalapiedra et al. 2021, doi:10.1093/molbev/msab293), eggNOG 5.0 DB (Huerta-Cepas et al. 2019) — OG COG1335
  • Curated reference: UniProt I6XD65 (SwissProt, reviewed; Evidence at protein level)
  • Intra-MTBC selection: pN/pS and disruption from SPDI variants of 142 601 MTBC strains (this work, local collection vs H37Rv NC_000962.3)
  • Genome-wide structure: AlphaFold DB model (Jumper et al. 2021, doi:10.1038/s41586-021-03819-2; Varadi et al. 2024, doi:10.1093/nar/gkad1011) searched vs PDB with Foldseek (mean pLDDT 97.3)
  • Catalytic-site verification: M-CSA (Ribeiro et al. 2018, doi:10.1093/nar/gkx1012), entry 716; catalytic residues aligned onto the structural model
  • Interaction network: STRING v12.0 (Szklarczyk et al. 2023, doi:10.1093/nar/gkac1000), taxon 83332, CC-BY 4.0 — 101 functional partner(s); context anchor pncB1
  • Essentiality: genome-wide transposon mutagenesis in H37Rv — DeJesus et al. 2017 (mBio, doi:10.1128/mBio.02133-16, CC BY)
  • Proteomics: integrated mass-spectrometry abundance from PaxDb 5.0 (Huang et al. 2023, doi:10.1016/j.mcpro.2023.100640), taxon 83332 — weighted average of 16 datasets, incl. Schubert et al. 2013 (doi:10.1016/j.chom.2013.04.008) and Albrethsen et al. 2013 (doi:10.1074/mcp.M112.018846)
  • Functional category: TubercuList scheme (Cole et al. 1998, doi:10.1038/31159), via Mycobrowser (Kapopoulou et al. 2011, doi:10.1016/j.tube.2010.09.006)
  • Orthologues: reciprocal best hits (DIAMOND, Buchfink et al. 2021, doi:10.1038/s41592-021-01101-x) against Mycobrowser release 5 reference proteomes
  • Experimental structures: PDBe/SIFTS UniProt→PDB mapping (Dana et al. 2019, doi:10.1093/nar/gky1114)
  • Genomic context / operon: H37Rv annotation; operon predicted by co-directional intergenic distance (Salgado et al. 2000, doi:10.1073/pnas.030539397)
  • Mutant phenotypes: standardized Tn-seq compendium MtbTnDB (Jinich et al. 2025, doi:10.1111/mmi.15370), aggregating many primary Tn-seq studies across conditions
  • Drug resistance: consolidated catalogue, WHO 2nd ed. 2023 (9789240082410) + tb-profiler; only the resistance-associated tier (grade 1–2) is surfaced
  • Physico-chemical properties: ExPASy ProtParam method via Biopython (Gasteiger et al. 2005), computed from the MTBC0 sequence
  • Predicted localisation: DeepTMHMM (Hallgren et al. 2022, doi:10.1101/2022.04.08.487609) for transmembrane topology and signal peptide
  • Primary literature: none located yet; annotation rests on the domain/homology sources above.

Ancestral MTBC0 protein sequence

>mtbc0_002176|Rv2043c|pncA
MRALIIVDVQNDFCEGGSLAVTGGAALARAISDYLAEAADYHHVVATKDFHIDPGDHFSGTPDYSSSWPPHCVSGTPGADFHPSLDTSAIEAVFYKGAYTGAYSGFEGVDENGTPLLNWLRQRGVDEVDVVGIATDHCVRQTAEDAVRNGLATRVLVDLTAGVSADTTVAALEEMRTASVELVCSS